DNA chip platform: a high-throughput genotyping technology for genetic diagnosis and pharmacogenetic profiling by LU YI
DNA CHIP PLATFORM: A HIGH-THROUGHPUT
GENOTYPING TECHNOLOGY FOR GENETIC
DIAGNOSIS AND PHARMACOGENETIC PROFILING
LU YI
(Bachelor of Science, Wuhan University, PR China)
A THESIS SUBMITTED
FOR THE DEGREE OF DOCTOR OF PHILOSOPHY
DEPARTMENT OF PAEDIATRICS
NATIONAL UNIVERSITY OF SINGAPORE
2005
iTHIS THESIS IS DEDICATED TO:
MY PARENTS
MY ELDER BROTHER





First of all, I would like to express my sincere gratitude and appreciation to my
principal supervisor, Dr. Yeoh Eng Juh Allen, Associate Professor, Department of
Paediatrics, National University of Singapore (NUS), for his invaluable guidance
during my studentship in NUS. His encouragement and constructive criticisms have
taught me to work independently, think scientifically, and understand the principles to
be a researcher. I am deeply appreciative of his advice and guidance over the years.
Secondly, I must thank Ms. Kham Kow Yin Shirley, Senior Lab Officer, Department
of Paediatrics, NUS. From the first day in this foreign land, “Auntie Shirley”, as she
is fondly known to everyone, has always cared for me in my study, my lab work, even
my daily life. Her kindness has helped me quickly adapt to this new environment
enabling me to devote my time into the research. Her useful advice, as well as her
help in all aspects, is truly unforgettable.
I also wish to record my sincere appreciation to Associate Professor Quah Thuan
Chong, Department of Paediatrics, NUS, and Dr. Heng Chew Kiat, Department of
Paediatrics, NUS, for their guidance and expert advice which enabled me to perform
my research systematically and their support in the review and revision of my
publications. I would also thank my colleagues in the laboratory for their warm
friendship and making me part of this research family.
Finally, my projects would not have started without financial aid from NUS research






Table of Contents iii
Summary viii
List of Tables x
List of Figures xii
List of Abbreviations xiv
Preface 1
Chapter 1: Introduction 3
1.1 β-thalassemia and β-globin gene 4
1.1.1 β-thalassemia 4
1.1.2 Techniques for the genetic diagnosis of β-thalassemias 9
1.1.2.1 The principle of the minisequencing 10
1.1.2.2 Applications of the minisequencing 12
1.2 Pharmacogenetic analyses in childhood acute lymphoblastic leukaemia 22
1.2.1 Childhood ALL and drugs commonly used in its treatment 23
1.2.2 Xenobiotics-metabolizing genes and their common polymorphisms 26
1.2.2.1 6-Mercaptopurine metabolism 26
1.2.2.2 Folic acid metabolism 29
1.2.2.3 Phase I and phase II enzymes 34
1.2.2.4 Drug transporters 39
iv
1.2.3 Statistical methods commonly used in the study of polymorphism-
disease association 41
1.2.3.1 Hardy–Weinberg equilibrium test 42
1.2.3.2 Chi-square (χ2) test 43
1.2.3.3 Z-test 44
1.2.3.4 Fisher’s exact test 45
1.2.3.5 Binary logistic regression 46
1.2.3.6 Linkage disequilibrium (LD) 46
1.2.3.7 Receiver operating characteristic (ROC) curve 48
1.2.3.8 Some important terms in statistical analysis 50
1.3 Aims 53
1.3.1 Screening β-thalassemia mutations using APEX methodology 53
1.3.2 Pharmacogenetic profiling of children with ALL using AsPEX strategy 54
Chapter 2: Materials and Methods 57
2.1 APEX genotyping platform for β-globin and TPMT genes 57
2.1.1 APEX methodology 57
2.1.2 DNA samples 58
2.1.3 PCR amplifications 59
2.1.4 APEX primers 61
2.1.5 Microarray preparation 63
2.1.6 Chip layout 64
2.1.7 Hybridization 64
2.1.8 APEX reactions 65
2.1.9 Fluorescence detection 66
2.1.10 Signal intensity analysis 66
v2.1.11 Tests on unbalanced PCR amplification 67
2.2 AsPEX genotyping strategy for pharmacogenetic profiling 67
2.2.1 Study design 67
2.2.2 Genotyping strategy 69
2.2.3 Multiplex PCRs and purification 71
2.2.4 Multiplex single nucleotide AsPEX 74
2.2.5 Chip layout and preparation 76
2.2.6 Hybridization 78
2.2.7 Fluorescence detection and analysis 78
2.2.8 Statistical analyses 79
2.2.9 Sensitivity comparison between APEX and AsPEX 81
2.2.10 Test on potential extension biases of AsPEX primers terminated
with different nucleotides 81
Chapter 3: Results 82
3.1 APEX genotyping platform for β-globin and TPMT genes 82
3.1.1 PCR amplifications 82
3.1.2 APEX reactions 83
3.1.3 Accuracy validation 86
3.1.4 Analyses of fluorescence intensity 88
3.1.5 Efficacy testing on unbalanced PCR amplification to generate
ssDNA 90
3.2 AsPEX genotyping strategy for pharmacogenetic profiling 91
3.2.1 PCR amplifications 91
3.2.2 Multiplex AsPEX reaction 91
3.2.3 Analyses of fluorescence intensity 96
vi
3.2.4 Genotype/allele frequencies of polymorphisms in Chinese, Malay and
Indian populations 105
3.2.5 Individual polymorphisms and the risk of developing childhood ALL 113
3.2.6 Combined genotypes and the risk of developing childhood ALL 117
3.2.7 Polymorphisms and the risk of ALL relapse 120
3.2.8 Sensitivity comparison between APEX and AsPEX 125
3.2.9 Signal intensity of the AsPEX primer pair with balanced
concentrations 126
Chapter 4: Discussion 128
4.1 Technical issues regarding the chip-based genotyping platforms 128
4.1.1 Comparison between APEX and AsPEX 129
4.1.2 Comparisons between APEX/AsPEX and commercial chip-based
genotyping platforms 131
4.1.3 Comparisons between APEX/AsPEX and other genotyping
techniques 133
4.1.4 Useful tips for the design of APEX/AsPEX DNA chip 135
4.1.5 Analyses of fluorescence intensity 138
4.1.6 Limitations of APEX and AsPEX 139
4.1.7 Future trends in genotyping technology 141
4.2 Polymorphisms in xenobiotics-metabolizing genes and their impact on
the risk of developing childhood ALL and risk of ALL relapse 143
4.2.1 Significant differences in allele frequencies among Chinese, Malay
and Indian populations 144
4.2.2 The impact of MTHFR C677T, RFC G80A and NQO1 C609T
polymophisms on the susceptibility to develop childhood ALL 145
4.2.2.1 MTHFR C677T 146
4.2.2.2 RFC G80A 148
4.2.2.3 NQO1 C609T 150
vii
4.2.2.4 The effects of combined genotypes 153
4.2.3 Factors that may alter the risk of relapse in children with ALL 156
4.2.4 Limitations of the study 158
4.2.5 Current obstacles in pharmacogenetics research of childhood





Genetic polymorphisms/mutations not only cause inherited diseases like Mendelian
single gene diseases, but may also, in concert, alter the risk of developing certain
cancers by defining an at-risk population, or affect a patient’s response to therapy by
altering the metabolism of therapeutic drugs or modulate their pharmacokinetics.
Therefore, systematical profiling of such polymorphisms/mutations may help to
document their prevalence, to understand the complexity of carcinogenesis, and to
optimize therapeutic efficacy by tailoring the dosages to an individual who is likely to
respond well to the drugs and will not suffer corresponding side effects. However,
these involve determining the polymorphisms of many genes in various individuals at
different times, making it critical to develop a single platform that is cheap, readily
customizable and can interrogate tens of polymorphisms in a single run.
β-thalassemia, caused by mutations in the β-globin gene, is the most common
inherited disease in the world. It causes decreased production of the β-globin which
creates an imbalance in α- and β-globin production resulting in anemia. Population
screening and prenatal diagnosis are currently the most effective measures to control
this disease. The first project for this thesis was to design a rapid and robust
methodology to simultaneously screen multiple mutations causing β-thalassemias.
We integrated the outstanding multiplexing capacity of DNA chip technology and
high accuracy of single-nucleotide primer extension strategy to establish an Arrayed
Primer Extension (APEX) genotyping platform capable of detecting 23
polymorphisms in β-globin gene and 9 polymorphisms in thiopurine S-
methyltransferase (TPMT) gene in a single assay. Two hundreds DNA samples with
known genotypes were used to validate this strategy. Accuracy of 97.3% and 100%
ix
for β-globin and TPMT genes, respectively, were achieved. Further analysis on
fluorescence intensities enabled us to set 2 cut-off values, 5.0 and 10.0, to determine
the genotype quantitatively. Our results show that APEX is a reliable strategy to
detect mutations causing β-thalassemia and TPMT deficiency.
The second project involved an investigation of the impact of 14 polymorphisms in 8
xenobiotics-metabolizing genes (TPMT, NQO1, MTHFR, GSTP1, CYP1A1,
CYP2D6, MDR1 and RFC) on the risk of developing childhood acute lymphoblastic
leukaemia (cALL) and the risk of relapse. ALL is the most common type of
paediatric cancer. Defective handling of environmental xenobiotics due to
polymorphisms in related metabolizing genes is one of the suspected reasons for the
development of cALL. In addition, since efficacy of drugs may be similarly altered
due to the polymorphic genes involved in drug metabolism, it is hypothesized that
these polymorphisms may influence a patient’s treatment response. Instead of using
conventional RFLP test which could only detect these polymorphisms individually,
we developed another DNA chip-based method by exploiting multiplex allele-specific
primer extension (AsPEX) which was able to detect all 14 polymorphisms
simultaneously. We screened 225 cALL cases and 334 controls, and found that
polymorphisms at NQO1-C609T, MTHFR-C677T and RFC-G80A are associated
with a reduced risk of developing cALL in Chinese and/or Malay populations.
However, we did not identify the influence of polymorphisms on the risk of relapse.
In conclusion, DNA chip platform is a high-throughput and reliable technology for
genetic diagnosis and pharmacogenetic profiling.
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1Preface
Although over 99% of the human genome is essentially identical, biological effects of
genetic variations in the remaining DNA sequences interacting with environmental
factors, account for the uniqueness of each individual (Roses, 2002.) The types of
genetic variations occurring in the human genome include point mutations,
deletions/insertions, gene rearrangements or extensions. Of all these variants, single
nucleotide polymorphisms (SNPs) are by far the most abundant, and are estimated to
occur at a frequency of 1 per 1,000 base pairs. As a whole, the human genome is
estimated to contain approximately ten millions of such nucleotide changes (Syvanen,
2001; Rebbeck, et al., 2004).
Majority of the SNPs, however, are located in non-coding regions of the genome and
have no known impact on the phenotype of an individual. These non-coding SNPs
are valuable in tracing migrational population genetics and evolutionary studies. Only
a small subset of SNPs results in significant phenotypic changes. These include SNPs
within genes that either alter the primary structure of the encoded proteins or interfere
with the expression of genes at transcriptional level like in the processing of the
primary transcripts, in the translation of mRNAs, or in the post-translational stability
of the gene products, accounting for most of the inherited monogenic disorders
(Syvanen, 2001).
Although the coding sequences (exons) may remain intact, SNPs that occur within
putative regulatory motifs or even in introns may also disrupt normal gene expression,
or worse, result in complete inactivation of transcription. Routine genetic testing for
2many SNPs that cause monogenic diseases is already in clinical practice. One well-
documented example is the mutations in β-globin gene that causes β-thalassaemia
syndromes. This was one of the research areas in our laboratory for many years and a
large number of samples with known mutations of the β-globin chain are available.
Another important group of SNPs are those that alter the normal functions of enzymes
involved in metabolisms of chemical xenobiotics such as environmental carcinogens
and medications. These SNPs are of particular interest to cancer epidemiological
studies or pharmacogenetic analyses. Childhood acute lymphoblastic leukaemia
(ALL) is the most common form of paediatric cancer worldwide and it is the subject
of a multi-centre treatment study, the Malaysia-Singapore ALL Study 2003, in our
laboratory. Environmental carcinogens have been implicated in various types of
cancer. Developing fetuses and growing infants may be particularly susceptible to
environmental carcinogens. Chemotherapeutic drugs used in the treatment of
childhood ALL have narrow therapeutic indices; it is critical to define the patients
who are likely to develop severe toxicity because of ineffective clearance of drug
because of their genetic variation in metabolising drugs. As such, it is interesting to
study the genetic profiles of local children to determine their risk of developing the
leukaemia, therapeutic efficacy and toxicity.
In this thesis, polymorphisms/mutations involving the β-thalassaemia and metabolic
enzymes for the drugs commonly used in treatment of children with ALL will be used
as models to explore the potential values of DNA chip-based genotyping strategies.
3Chapter 1 Introduction
β-thalassaemia is the most common inherited disease in the world. In the
heterozygous state – β-thalassaemia minor – the carrier has mild microcytosis but
otherwise asymptomatic. It has been postulated that carriers of β-thalassaemia minor
has less severe malaria infections and this provides an evolutionary advantage to the
carrier in places of high prevalence of malaria. Unfortunately, in the homozygous
state – β-thalassaemia major – the patient suffers from severe anaemia, is transfusion
dependent for life and will perish by 30 years of age in the absence of proper iron-
chelation therapy.
Although medical therapies for β-thalassaemia major, like chronic blood transfusion
with concomitant iron chelation, are currently available and able to prolong the life
span of β-thalassaemia major patients, poor patient compliance and high costs limit
their roles. In the United Kingdom, the estimated cost of managing a β-thalassaemia
major patient in his lifetime was a staggering £803,002 (Karnon, et al., 1999)!
Similarly, in Sri Lanka the average cost of treating one patient for a year was about
US$2,465 (de Silva, et al., 2000), more than doubled their per capita income of
US$1,200. Unfortunately, thalassaemia is a “poor man’s disease”; the cost is also
certainly beyond the reach of most ASEAN countries where it is highly prevalent.
Antenatal genetic diagnosis to detect β-thalassaemia major fetuses followed by
therapeutic abortion is much effective as a national measure (Olivieri, 1999) and has
been the successfully implemented in Singapore for the last 30 years.
4Modern effective therapy of childhood ALL is treated using up to 9 different
chemotherapeutic drugs used in combinations. These drugs target different but
complementary pathways in DNA synthesis and cell division as such work
synergistically to maximise leukaemia cell kill while minimising side-effects. A host
of metabolizing enzymes and transporters is involved in the breakdown of these drugs.
With more than 80% of children with ALL cured in Singapore and developed
countries, further improvements in childhood ALL therapy must come from tailoring
therapy to maximise the efficacy while reducing and preventing adverse drug
reactions.
This chapter provides a broad overview of β-thalassaemia and childhood ALL
described in this thesis:. General introduction about β-thalassaemia will be first
presented, followed by a review of the current methods used in its genetic diagnosis.
1.1 β-thalassaemia and β-globin gene
1.1.1 β-thalassaemia
Diseases of the haemoglobin – haemoglobinopathies – are divided into 2 major
groups: thalassaemia and structural haemoglobinopathies. Thalassaemia results from
decreased production of either α- and β-globin chains, causing an imbalance in the
ratio α- and β- globin chains in the red cells. Unlike structural haemoglobinopathies
for example sickle haemoglobin (HbS), where the haemoglobin produced is abnormal,
in thalassaemias, the globin gene is normal but the affected globin protein is not
produced at all or produced in significantly reduced quantities.
5β-thalassaemia is a heterogeneous group of autosomal recessive disorders
characterized by markedly reduced or absent β-globin production. Because of the
absent β-globin, the consequent imbalance of ratio of α- and β-globin in the red cells,
causes precipitation of the excess α chains into insoluble aggregates that leads to
destruction of the developing erythrocyte resulting in ineffective erythropoiesis
(Weatherall, et al., 2001).
β-thalassaemia is highly heterogeneous at the molecular level. To date, nearly 200
different mutations in β-globin gene have been described (Olivieri, 1999). The
majority of these genetic defects are single nucleotide substitutions affecting critical
areas in the promoter or early part of the gene resulting in severely reduced
production of β-globin (Cao, et al., 1994). These mutants can be further classified
under the following categories:
 nonsense and frameshift mutants which produce premature termination;
 RNA processing mutants which disrupt splicing, interfere with RNA cleavage
or polyadenylation;
 transcriptional mutants which disrupt the function of the promoter; and
 mutations in the initiation or Cap site.
These mutations result in either the absence of the synthesis of β-globin chains
(termed as β0-thalassaemia) or a severely reduction in their synthesis (termed as β+-
thalassaemia). β+-globin mutations are rare in Southeast Asia region and will not be
discussed further. Unlike α-thalassaemia, total deletions of the gene or the locus
control region are uncommon (Cao, et al., 1994).
6At the phenotypic level, β-thalassaemia can be classified into 2 clinical syndromes: β-
thalassaemia trait, characterised by asymptomatic microcytosis, results from the
inheritance of one mutant β-globin gene; and thalassaemia major (β0- or β+-
thalassaemia), which usually result from homozygosity or compound heterozygosity
for a mutant β-globin allele. β-thalassaemia major patients are dependent on regular
transfusions to survive. Detailed biology and clinical features of β-thalassaemias are
beyond the scope of this thesis and have been well reviewed (Weatherall, et al., 2001).
A common structural haemoglobinopathy resulting from a point mutation inside the
β-globin gene in Southeast Asia region is the HbE. This results in production of an
abnormal (hence structural) β-globin that is also produced in reduced amounts. By
itself, whether in β-thalassaemia mutation as a compound heterozygote – HbE-β-
thalassaemia – a moderately severe anaemia, in between that of thalassaemia minor
and major, afflicts the patient. This is termed thalassaemia intermedia.
Southeast Asia lies in the malaria belt where for thousands of years, malaria is the
major cause of death and morbidity. As thalassaemia disorders confers protection
against severe malaria, the evolutionary Darwinian pressure results in a very high
frequency of thalassaemia gene carriage and other haemoglobinopathies like HbE in
the region (Weatherall, et al., 2001). In Thailand, it has been estimated by the World
Bank that, over the next 30 years, approximately 100,000 new cases of HbE-β-
thalassaemia alone will be added to the Thai population. In Indonesia, the frequencies
of HbE were reported as 10% in newborns and 22% in pregnant women (Timan, et al.,
2002). In Singapore, we have reported that the carrier frequency for β-thalassaemia
7mutations was 2.7% in the Chinese, 6.3% in Malays, and 0.7% in Indians (Kham, et
al., 2004).
Asia is home to the fastest expanding populations in the world. This together with the
high frequencies for thalassaemia disorders in Southeast Asia and the Indian
subcontinent, imply that there will be a massive increase in the number of children
with thalassaemia major and intermedia who will require a huge number of safe red
blood concentrates and expensive iron chelation therapy to remove the excess iron
from blood transfusion. The economic burden of this rapidly ticking time-bomb
together with the AIDS epidemic which further threatens the safety of blood supply,
will increase the already strained the health resources for ASEAN country,
smothering their newly acquired emergence from the poverty and depriving them of
the benefits of globalisation.
Professor Wong Hock Boon from Department of Paediatrics, National University of
Singapore has recognised this health epidemic of β-thalassaemia major more than 30
years. He instituted a highly successful antenatal screening program that has
dramatically reduced the numbers of newborns with β-thalassaemia major from 15 to
less than 1 per year (Figure 1.1) (Ng and Law, 2003).
8Figure 1.1 The number of β-thalassaemia major born in Singapore (Ng and Law,
2003).
What Professor Wong did was ingenious. The wide-spread use of automated blood
cell counters provided a full blood count report that includes both the red blood cell
count and mean corpuscular volume. Healthy carriers of β-thalassaemia mutations
have both low mean corpuscular volumes (causing the red blood cells to be small –
microcytosis) and a relatively increased number of red blood cell counts to
compensate for the mild anaemia. Professor Wong launched a series of education of
all obstetricians in Singapore to scrutinise every pregnant women’s mean corpuscular
volume when they present for antenatal check up. For all women who were found to
have microcytosis, a thalassaemia screen and test for iron deficiency were carried out.
If the mother was found to be a thalassaemia carrier, the father would also be screened
for thalassaemia carriage. When both parents were found to be thalassaemia carriers,
antenatal diagnosis using initially amniocentesis and subsequently chorionic villus
sampling, were carried out to determine if the fetus had thalassaemia major. As β-
thalassaemia is an autosomal recessive condition, there is a 1 in 4 chance that the fetus
9is affected. If the fetus is found to be β-thalassaemia major, termination of pregnancy
can be offered.
On a national scale, in order to determine the impact of β-thalassaemia on the health
burden in the country and survey the common mutations, a rapid, easily customizable
platform will be extremely helpful (Rund and Rachmilewitz, 2005). This will allow
the government to plan for resources to manage this impending epidemic (Kham et al.,
2004)
1.1.2 Techniques for the genetic diagnosis of β-thalassaemias
Over the past few decades, genetic diagnosis of common mutations in the β-globin
gene has been conducted by a variety of techniques, including restriction fragment
length polymorphism (RFLP) (Old, et al., 1984), allele-specific oligonucleotide (ASO)
hybridisation (Cai, et al., 1988), denaturing gradient gel electrophoresis (DGGE) (Cai,
et al., 1990), multiplex amplification refractory mutation system (ARMS) (Fortina, et
al., 1992), and reverse dot-blot (RDB) analysis (Sutcharitchan, et al., 1995).
Although each of these methods has its advantages, some are very time-consuming or
labor-intensive; moreover, none of them is able to detect many mutations in a single
assay (Table 1.1).
More recently, the principle of single nucleotide primer extension, also known as
“minisequencing”, is increasingly used as the reaction principle of choice for high-
throughput SNPs genotyping because of its high specificity in distinguishing between
sequence variants (Syvanen, 1999).
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Table 1.1 Features of traditional genotyping methods.
Method Principle Advantage Disadvantage Comment
RFLP Specific endonuclease
cleavage










ARMS Selective extension by
Taq polymerase
Simple and cheap Difficult to
troubleshoot
--
DGGE Differential mobility of
DNA strands











1.1.2.1 The principle of the minisequencing (Figure 1.2)
In a minisequencing assay, the DNA region spanning point mutations to be detected is
initially amplified by PCR. An oligonucleotide primer, which is complementary to
the DNA region immediately adjacent to the site of the mutation, is designed to
hybridise to the target DNA strand. A thermostable DNA polymerase without
proofreading activity is used to specifically extend the primer with one fluorescent or
radioactive dideoxynucleotide triphosphate (ddNTP) complementary to either the
mutated nucleotide or the normal one. In samples from homozygous individuals, only
one labelled ddNTP will be incorporated in the primer while in samples from
heterozygous individuals the primer can be extended with two different ddNTPs. An
additional separation step is usually required after the minisequencing reaction to
separate the labelled primer from the reaction mix before the measurement. In
practice, the choices of the label and the method of post-minisequencing separation
determine the format of a minisequencing assay.
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Figure 1.2 The principle and steps of the minisequencing assays exemplified by
analysis of a G-to-A transition (Syvanen, 1999).
A major advantage of the minisequencing reaction principle over the widely applied
ASO hybridization is that the distinction between the sequence variants is based on
the high accuracy of the nucleotide incorporation catalyzed by the DNA polymerase,
instead of on the differences in thermal stability between mismatched and perfectly
matched hybrids formed with ASO probes. Therefore, the minisequencing allows
excellent discrimination between the homozygous and heterozygous genotypes and
the reaction is robust and insensitive to small variations in the reaction conditions.
Furthermore, the same reaction conditions can be employed for detecting any
nucleotide change, independent of both the type of the polymorphism and the
sequence carrying the mutation. These features are advantageous for high-throughput
applications because the effort required for assay design and optimisation are
minimised (Syvanen, 1999).
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In the next section, some common applications of the minisequencing methodology
for various diagnostic purposes will be reviewed.
1.1.2.2 Applications of minisequencing
Minisequencing-based methods are highly versatile and have been applied in a large
number of studies to analyse point mutations for the diagnosis of both inherited and
somatic genetic disorders (Kuppuswami, et al., 1991; Hietala, et al., 1996) as well as
for the screening of recessive diseases carriers (Pastinen, et al., 1997). The methods
have also been used for analysing biallelic sequence variation caused by SNPs in the
identification of individuals (Syvanen, et al., 1993), for tissue typing (Tully, et al.,
1996), for analysing DNA methylation (Gonzalgo et al., 1997), and in genetic
mapping and association studies (Pastinen, et al., 1998).
Applications exploiting the minisequencing methodology to screen β-thalassaemia
mutations have also been reported and these will be briefly described below. Coupled
with various post-minisequencing processes, many genotyping strategies have been
established. Depending on different assay formats, those strategies can be simply
classified into liquid-phase and the solid-phase reaction strategies.
Liquid-phase assay formats
In these formats, minisequencing primers for allele detections are free reactants in the
solution. After primer extension reaction, various methods of primer separation and
signal detection determine the diversity of genotyping strategies.
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i) Minisequencing/denaturing high-performance liquid chromatography (DHPLC)
In 2003, Wu, et al., (2003) reported the application of using the minisequencing
followed by denaturing high-performance liquid chromatography for simultaneous
detection of five most common mutations in the β-globin gene in Chinese populations.
Their methodology involved the amplification of the β-globin target sequence
followed by a purification step, a multiplex minisequencing, and a fully-denaturing
DHPLC analysis. DHPLC detects polymorphisms by monitoring the DNA mobility
using chromatography in a denaturing condition. The WAVE® DNA analysis system
(Transgenomic Inc., San Jose, CA) is commonly used in DHPLC analysis. Since
different ddNTP is incorporated into the minisequencing primer for wild-type and
mutant sequences respectively, the molecular weight of the primer will be slightly
different after the extension. Such a difference will be subsequently reflected as a
different elution time on the chromatogram, which is a function of both the size and
base composition of the primer. Compared with the DHPLC profiles of normal
controls, the genotype of tested sample can be given (Figure 1.3). The advantage of
using the WAVE system is that unlabelled ddNTPs can be used to save the cost, and
analytical run time is short (usually within 15 min). Besides, if equipped with WAVE
Accelerator or the fluorescence detector, the throughput can be further increased or
even doubled. Similar work has been done by Yip, et al., (2003) who adopted
minisequencing/DHPLC to genotype 5 common Southeast Asian β-thalassaemia
mutations.
14
Figure 1.3 DHPLC analyses of extension products generated by multiplex
minisequencing (Adopted from Yip, et al., 2003).
ii) Minisequencing/capillary electrophoresis (CE)
Capillary electrophoresis is another frequently used method to separate extended
primers after minisequencing. Wang, et al., (2003) presented a rapid screening
procedure based on fluorescence-based multiplex minisequencing followed by gel
electrophoretic size separation to detect 15 Southeast Asian and Indian β-thalassaemia
mutations. In her work, 15 minisequencing primers were divided into two panels for
multiplex primer extension. Within each panel, each primer differed in total length by
adding variable-length non-specific polynucleotide tails to the N-terminals of the
primers. After multiplex minisequencing, CE was used to differentiate those primers
based on size, and their corresponding peaks appeared at different location on the
electrophoretogram. The size of the primer defined the position of the polymorphism
while the fluorescent ddNTP by which the primer became extended gave the identity
of the nucleotide at each side. Compared with the peak profile of normal control, the
genotype of the tested sample was given (Figure 1.4). Wang evaluated this method in
a double-blind validation analysis consisting of 81 β-thalassaemia patient samples and
8 wild-type controls, and achieved 100% accuracy in genotyping. Nowadays, ready-
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to-use reaction kits, standard protocols and relevant instruments are commercially
available, such as SNaPshot™ Multiplex Ready Reaction Mix and ABI PRISM® 3100
Genetic Analyser (Applied Biosystems). This convenience makes this type of
minisequencing assay very easy to set up.
Figure 1.4 CE analyses of extension products generated by multiplex minisequencing
in ABI PRISM® 3100 Genetic Analyser (Adopted from Wang, et al., 2003).
iii) Minisequencing/fluorescence polarization (FP)
Besides the strategies using minisequencing followed by various size-based
identifications, fluorescence polarization detection is a comparatively new
homogeneous technology with high reproducibility. The first application of the
minisequencing and subsequent FP detection for β-thalassaemia diagnosis was
reported by Mo, et al., (2004). Using such a methodology, Mo and his colleagues
established a system to simultaneously detect 8 common causative mutations in the β-
globin gene in Chinese. FP is based on the principle that if plane-polarized light is
shone on fluorescent dye labels in solution, the molecules tumble rapidly, and the
emission is depolarized. If the viscosity and temperature are constant, FP is directly
proportional to the molecular volume, which is directly proportional to the molecular
weight (Figure 1.5a). When ddNTP labelled with different fluorophores is linked to
the primer in the minisequencing reaction, the molecular weight of the dye is changed.
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The genotype of the target DNA can be determined simply by exciting the fluorescent
dye and determining the change in FP (Figure 1.5b and 1.5c). Mo used two types of
dyes, R110 and TAMRA, to label ddNTPs corresponding to wide-type and mutant
nucleotides respectively for each mutation site. By measuring their respective FP
after cyclic minisequencing, maximally 48 samples could be genotyped together in
Mo’s system. The merit of FP detection is that the equilibrium can be reached very
rapidly thus the measurement can be done immediately after minisequencing, unlike
DHPLC or CE. However, multiplex minisequencing is not applicable in such a
method. Individual reaction mix should be prepared for each mutation in
minisequencing.
Figure 1.5 The principle of minisequencing/FP genotyping strategy (Adopted from
Kwok, 2002).
[a] Fluorescence polarization (FP)
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[b] Scheme for minisequencing/FP genotyping strategy
[c] Result demonstration
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Although liquid-phase minisequencing coupled with various post-minisequencing
analyses has been successfully performed in many applications, they have a notable
drawback. The major problem of conducting liquid-phase minisequencing is the
difficulty of setting up a workable multiplex reaction as potential primer-primer
interactions limit the number of primers in the same reaction. Hence the number of
genes that can be interrogated simultaneously will be limited.
To overcome the disadvantages of liquid-phase assay formats, a feasible solution is to
design the minisequencing assay on the solid phase, for example, on the DNA chip
platform.
Solid-phase assay formats
In solid-phase assay formats, oligonucleotide reactants, either templates or
primers/probes, are immobilised onto a certain solid support, such as a glass
microscopic slide or 384-well microtitre plate, to form a DNA chip, or synonymously,
a microarray.
Within the last decade, exploitation of the microarray platform has enabled the large-
scale analysis of known sequence variants on a chip. Immobilization of specific
oligonucleotide sequences on the chip surface is a frequently proposed approach for
multiplex genotyping of SNPs (Shi, 2001). A solid support, usually the glass slide,
allows precise sizing of the spots, accurate quantification of the signal as well as
dimensional stability and rigidity. More importantly, immobilization of
oligonucleotides at different locations prevents unwanted interactions among different
primers, the major cause of false-positive results in single-tube liquid-phase reactions.
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This advantage facilitates the design of appropriate primers and provides great
potential for a high-throughput multiplex reaction.
Due to its flexibility in the design of a microarray, the DNA chip platform is able to
incorporate different mutation-detecting strategies, some of which will be described
below.
i) ASO hybridisation
Differential hybridisation with ASO probes is probably the most commonly used
reaction principle on the DNA chip platform. Foglieni, et al., (2004) described a
method of using a commercially available microelectronic platform, the NanoChip™
Molecular Biology Workstation by Nanogen®, to identify the nine most frequent β-
thalassaemia mutations in the Mediterranean area. This system enables deposition
and concentration of charged samples to designated test sites on a 100-microelectrode
formatted cartridge. A thin hydrogel permeation layer containing streptavidin coats
the chip surface, allowing binding of the biotinylated PCR products amplified from
patient DNA. Stabilisers and fluorescence-labelled oligonucleotide probes for each
allele are hybridised, and the chip is then washed and imaged. Fluorescence signal
ratios of the probes allow discrimination between homozygotes and heterozygotes for
a particular SNP.
ii) Allele-specific primer extension (AsPEX)
Previous work has shown that DNA polymerase-catalysed primer extension
discriminated between genotypes more than ten-fold better than the hybridisation with
ASO probes in the same microarray format (Pastinen, et al., 1997). Chan, et al.,
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(2004) developed a thalassaemia array using the principle of allele-specific primer
extension for the simultaneous analysis of 23 β-globin gene defects. Allele-specific
primer extension uses the differential amplification efficiency of two homologous
primers that differ only in their 3’-end nucleotides. Each primer is a perfectly
matched complement for the normal or mutant allele. In the chip format, all primers
are immobilised on DNA chip and subjected to following nucleotide incorporation
usually using fluorescence-labelled deoxynucleotide triphosphate (dNTP). Only
perfectly matched primers will be extended with the dye, emitting signals at specific
wavelengths which will consequently reveal the polymorphic sites queried. The high
fidelity of this method was confirmed in Chan’s report with 100% sensitivity and
specificity in the detection of 120 β-thalassaemia mutants. A notable advantage of his
method is that the reaction carried out on the chip ensures that the fluorescent signal
generated by the dye binding to the primer is indicative of the intended primer
extension, and not confounded by undesired side reactions such as primer dimers.
iii) Arrayed primer extension (APEX) (Figure 1.6)
The arrayed primer extension is a similar technique to AsPEX but uses only one
primer to detect each polymorphism (Their comparison will be discussed in Section
4.1.1, Chapter 4). Kurg, et al., (2000) described an integrated system with chip and
template preparation, multiplex primer extension on the array, fluorescence imaging,
and data analysis. In this methodology, detection primers are covalently immobilised
at different locations on a glass support. This spatial isolation allows a large number
of primers to be extended simultaneously without any primer-primer interference. In
Kurg’s method, the target DNA region was amplified by PCR, digested enzymatically,
and annealed to the immobilised primers, which promoted sites for template-
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dependent DNA polymerase extension using fluorescently labelled ddNTP. A
mutation was detected by a change in the fluorescence of the primer site. Kurg
applied this methodology to simultaneously analyse 10 β-thalassaemia point
mutations. His results showed that the signal-to-noise ratio of the APEX reaction
could reach as high as 40:1, enabling the identification of heterozygous mutations
with a high confidence level. APEX integrates the high accuracy of the
minisequencing and the great multiplexing capacity of the DNA chip, thus becoming
a good choice for genotyping purpose.
Figure 1.6 The principle of arrayed primer extension. The fluorescence on each slide
refers to the specific nucleotide. Homozygosity will display a single fluorescent spot
while heterozygosity will display two fluorescent spots.
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The following Section 1.2 will describe the second topic in this thesis: using DNA
chip-based genotyping platform to obtain pharmacogenetic profiles of children with
acute lymphoblastic leukaemia.
1.2 Pharmacogenetic analyses in childhood acute lymphoblastic
leukaemia (ALL)
It was mentioned in the Preface, SNPs may affect the functions of gene products.
Polymorphisms in genes encoding drug-metabolising enzymes, drug transporters and
drug receptors may affect the efficacy and toxicity of the drugs used in the treatment
of various diseases. These polymorphisms are usually the targets in
pharmacogenetics studies.
In brief, pharmacogenetics is about how to characterise a person with respect to
disease susceptibility, adverse drug reactions (ADR) associated with taking a
medicine, or whether the medicine is effective for treatment or prevention of a disease
(Roses, 2002). The purpose of a pharmacogenetics test is to detect DNA sequence
variations with the intention of predicting a differential drug response including
differences in efficacy, drug-drug interactions, and the relative risk of an adverse
response to various drugs. The ultimate promise of pharmacogenetics is to enable
doctors to select “the right medicine for the right patient at the right dose” by tailoring
the therapy according to individual genetic make-up. Genotypic stratification of
patients may improve cure for potentially fatal diseases like cancer by maximising
efficacy by using drugs for those who are more likely to respond and to reduce ADR.
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The presence of alleles associated with reduced response to a certain drug may guide
the selection of alternative therapies.
One part of this thesis will focus on the disease risk analyses in childhood acute
lymphoblastic leukaemia, which is the subject of interest in our laboratory. Later
sections will briefly introduce this form of paediatric cancer and review some
publications in this area.
1.2.1 Childhood ALL and drugs commonly used in its treatment
Acute lymphoblastic leukaemia is the most common form of cancer in children,
accounting for approximately 25% of all paediatric tumours and almost 75% of
childhood leukaemias (Sinnett, et al., 2000). It is a haematological malignancy,
characterised by an uncontrolled proliferation and maturation arrest of lymphoid
progenitor cells in the bone marrow, resulting in an excess of malignant cells.
Detailed information describing clinical symptoms, subtypes, pathophysiology and
the treatment of childhood ALL is beyond the scope of this thesis and has been
comprehensively reviewed elsewhere (Pui, 2003).
Although there is still no definite way of determining the cause of ALL, the
leukaemogenesis has been proposed as a conclusion of multiple genetic hits, where
external factors modulated by a series of genes modify the individual’s risk of
developing the leukaemia (Sinnett, et al., 2000). Childhood ALL is curable.
Successful treatments that began in the 1970s gave rise in the 1990s to a model that
predicts the risk of disease recurrence and adjusts the therapy based on host
characteristics, age, multiple disease characteristics including white blood cell (WBC)
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count, karyotype, DNA index and immunophenotype, and complex characteristic of
early response to therapy (Sather, 1986; Smith, et al., 1996; Felix, et al., 2000). At
the National University Hospital (NUH), Singapore, 3 treatment protocols have been
used in the therapy of childhood ALL: NUH protocol (1988-1996) (Quah, et al.,
1996), HK-SG ALL (1997-2002) and Ma-Spore ALL 2003 (2002- ).
Currently, in Singapore, approximately 80% of childhood ALL patients are cured.
This is a result achieved largely by improved scheduling, dosing and optimised
combination of existing drugs used for more than 30 years. Two important drugs are
described below:
6-Mercaptopurine (6-MP)
6-Mercaptopurine forms the backbone of ALL maintenance therapy. As a prodrug, it
requires bioactivation by a multistep pathway to form thioguanine nucleotides (TGN),
the major cytotoxic compound which are incorporated into DNA and induce
antileukemic effect. The metabolism of 6-MP is illustrated in Figure 1.7.
Figure 1.7 The metabolism of 6-MP. 6-MP, 6-mecaptopurine; 6-TGN, 6-thioguanine
nucleotide; HPRT, hypoxanthine phosphoribosyltransferase; IMPD, inosine




Methotrexate plays a central role in ALL therapy and targets several critical aspects of
folate metabolism (Chabner, et al., 2001). MTX inhibits dihydrofolate reductase
(DHFR) in the folate cycle. Both MTX and its polyglutamated form (MTXPG)
produced by cytosolic folylpolyglutamate synthetase (FPGS) bind to DHFR to inhibit
formation of tetrahydrofolate (THF), a required cofactor for both thymidylate and de
novo purine biosynthesis (Pui, 2003). MTX disposition is illustrated in Figure 1.8.
Figure 1.8 Overview of MTX disposition and effects in leukemic lymphoblast. MTX,
methotrexate; MTXPG, methotrexate polyglutamates; RFC, reduced folate carrier;
DHFR, dihydrofolate reductase; FPGS, folylpolyglutamate synthetase; TS,
thymidylate synthetase; THF, tetrahydrofolate; DHF, dihydrofolate.
Other drugs commonly used in childhood ALL chemotherapy include L-asparaginase,
prednisone (or prednisolone), dexamethasone, vincristine, and etoposide, most of
which take their effects through enzymatic activations, ligand-receptor interactions as
well as downstream reactions, or other metabolic pathways. The next section will
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focus on the genes involved in drug metabolism and the genes that potentially alter
genetic susceptibility to childhood ALL.
1.2.2 Xenobiotics-metabolising genes and their common polymorphisms
The genes described below have been studied in childhood ALL, although the roles of
some in childhood ALL remained controversial. The following sections are organised
according to the functions of respective gene products. Previous publications
describing the associations between the polymorphisms in those genes and childhood
ALL will be reviewed as well.
1.2.2.1 6-Mercaptopurine metabolism
Thiopurine S-methyltransferase (TPMT)
Investigations of thiopurine metabolism offer the first and still the most compelling
example of clinical relevance of pharmacogenetics in paediatric oncology (Aplenc, et
al., 2004). Previously (Section 1.2.1), I have described the relevant pathway which
involves the multi-step conversion of 6-MP to cytotoxic 6-TGN (Figure 1.7).
The amount of active 6-TGN accumulated in the cells is a balance of catabolism by
TPMT and activation by HPRT. Influence by polymorphisms of HPRT has not been
seen; the activity of TPMT in an individual determines the levels of active 6-TGN and
its efficacy and toxicity. TPMT is a cytosolic enzyme ubiquitously expressed in the
human body and catalyses the S-methylation of 6-MP into non-cytotoxic forms thus
resulting in detoxification of the drug.
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The gene encoding TPMT is located on chromosome 6p22.3 and has many genetic
polymorphisms, with heterozygous individuals (6-11% of Caucasians) having
intermediate TPMT activity and homozygous mutant individuals (0.2-0.6% of
Caucasians) having very low TPMT activity (Stanulla, 2005). Several independent
studies have demonstrated that TPMT genotype shows high concordance with its
phenotype (McLeod, et al., 2000; Schaeffeler, et al., 2004). Patients with severe
TPMT deficiency due to homozygous mutant alleles tend to accumulate very high
levels of thioguanine nucleotides (TGN); they experience severe life-threatening
haematopoietic toxicity if they are treated with standard doses of 6-MP, azathiopurine,
or 6-TG. Patients with heterozygous TPMT alleles has intermediate levels of TPMT
activity, accumulate more TGN after 6-MP or 6-TG therapy than do those
homozygous for wild-type TPMT alleles. Although these patients require modest
reductions in drug doses, they have improved outcome but at risk of developing
secondary AML and brain tumours if cranial irradiation is administered (Relling, et al,
1998).
To date 20 variant alleles have been identified in TPMT gene (Stanulla, et al., 2005),
and at least 10 variations have been associated with low TPMT enzyme activity
(McLeod, et al., 2002). Among them, three variants (TPMT*2, TPMT*3A and
TPMT*3C) account for up to 95% phenotypes of low TPMT activity. TPMT*2 allele
contains a G238C transversion mutation that reduces S-methylation 100-fold in yeast;
TPMT*3A allele consists of 2 mutations, G460A and A719G, that reduce TPMT
protein levels 200-fold in yeast, leaving no detectable activity (Yates, et al., 1997).
TPMT*3A has a frequency of approximately 10% in Caucasian population, but is
rarely observed in East Asian population, where TPMT*3C (A719G) is the most
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common. Besides TPMT*3A and TPMT*3C, TPMT*6 (A539T) is also found in
Southeast Asia (Kham, et al., 2004).
Pharmacogenetic studies of TPMT
The genotype-phenotype correlation of TPMT has been well established and widely
recognised. ALL patients homozygous for TPMT mutant alleles experience severe or
fatal myelotoxicity when treated with standard dose of 6-MP (50-75 mg/m2/day)
(McLeod, et al., 2000). These homozygous patients can tolerate only 5-10% of
protocol dose; reductions maybe necessary in heterozygotes (McLeod, et al., 2000).
Studies from St Jude Children’s Research Hospital showed that when patients were
treated correctly using pharmacologically adjusted dosing according to phenotype or
genotype, carriers of variant TPMT alleles experienced even better outcomes than
those with wild-type TPMT (Relling, et al., 1999; McLeod, et al., 2000). A study of
182 children with ALL demonstrated that 6-MP dose intensity was the strongest
predictor of outcome; a tendency toward better event-free survival was described for
children with intermediate and low TPMT activity compared with that of wild-type
TPMT phenotypes (Relling, et al., 1999). Similarly in Denmark (Schmiegelow, et al.,
1995), patients with lower than median RBC TGN concentrations experienced more
relapse probably due to inadequate dosing. Moreover, patients with TPMT deficiency
may have increased risk of developing brain tumours when treated with
antimetabolites and cranial radiotherapy (Relling, et al., 1998). Hence it is important
to know a patient’s TPMT genotype to enable appropriate dose adjustments.
Interestingly, although patients carrying known TPMT mutant genes always have
lower TPMT activity, some patients with low TPMT activity or sensitivity to 6-MP do
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not have any mutation in their TPMT genes. A long-term investigation is still
necessary to understand the prognostic value of TPMT polymorphism in ALL therapy.
1.2.2.2 Folic acid metabolism
Methylenetetrahydrofolate reductase (MTHFR)
The previous section 1.2.1, have described the influence of MTX on the folate
metabolic pathway. Methylenetetrahydrofolate reductase is an enzyme catalysing the
conversion of 5,10-methylenetetrahydrofolate (5,10-methylene-THF) to 5-
methyltetrahydrofolate (5-methyl-THF) in folic acid cycle (Figure 1.9). This
transformation is interrupted by MTX, which inhibits the formation of 5,10-
methylene-THF.
Figure 1.9 Overview of folic acid metabolic pathway and the role of MTHFR
(adopted from Skibola, et al., 1999). MTHFR, methylenetetrahydrofolate reductase;
SAM, S-adenosylmethionine; SAH, S-adenosylhomocysteine, DHF, dihydrotetrafolic
acid; THF, tetrahydrofolic acid.
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The MTHFR gene maps to chromosome 1p36.3 and contains 11 exons that span
13,454 base pairs. To date, 5 non-synonymous polymorphisms have been deposited
into public databases. Among them, two common mutations, a C to T transition at
nucleotide 677 (MTHFR C677T) and an A to C transversion at position 1298
(MTHFR A1298C), have been frequently studied previously (Frosst, et al., 1995;
Weisberg, et al., 1998; van der Put, et al., 1998). The T677 variation causing alanine
to valine substitution at the codon 222 affects the catalytic domain, leading to a
thermolabile enzyme with only 50% catalytic activity. The C1298 variation causing
the replacement of glutamate by alanine at codon 429 affects the regulatory domain.
On its own, this polymorphism does not result in decreased enzyme activity, but in
association with MTHFR C677T, it may lead to hyperhomocysteinaemia (van der Put,
et al., 1998).
Decreased MTHFR activity may lead to an increase of the 5,10-methylene-THF pool
at the expense of a decrease in 5-methyl-THF pool, thus reducing uracil
misincorporation in DNA, lowering the risk of chromosome breaks and consequently
decreasing the risk of developing leukaemia (Krajinovic, et al., 2004a). However, an
increased level of 5,10-methylene-THF, as well as dTMP, may enhance DNA
synthesis and counteract the effect of MTX (Krajinovic, et al., 2004b).
Pharmacogenetic studies of MTHFR
Due to the important role of MTX in ALL therapy, MTHFR genotypes have been
frequently evaluated in ALL. Nearly all studies focused on these 2 polymorphisms:
MTHFR C677T and MTHFR A1298G.
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Taub, et al., (2002) reported that leukemic blasts from 6 patients with the MTHFR
C677T polymorphic allele had increased in vitro sensitivity to MTX. This suggests
that patients with the variant allele should have a decreased risk of relapse. However,
the small number of patients precluded meaningful conclusions about the impact of
the polymorphism on the risk of relapse. Krajinovic, et al., (2004b) investigated the
role of C677T and A1298G in 201 patients treated on Dana Farber Cancer Institute
(DFCI) protocols DFCI 87-01, DFCI 91-01 and DFCI 95-01. The 201 patients had
MTX exposure of 4 g/m2 in induction and 30 mg/m2 i.v./i.m. each week during
maintenance therapy. Events were defined as leukaemia relapse or death from disease.
While neither polymorphism alone was significant on univariate analysis, the
MTHFR T677A1298 haplotype carried an increased risk of relapse, with a hazard
ratio (HR) of 2.2 (95% CI 1.0-4.7). Moreover, the combination of this haplotype with
the thymidylate synthetase (TS) triple repeat allele demonstrated a statistically
significant reduction in event-free survival (EFS), with a HR of 9.0 (95% CI 1.9-42.8).
These results supported the hypothesis that multiple polymorphisms in the folate
pathway might interact to alter treatment response in childhood ALL. In another
study with a larger sample size, Aplenc, et al., (2005) evaluated the roles of C677T
and A1298C on relapse in 520 patients. He found that C677T variant allele was
significantly associated with relapse, and this association remained significant (HR =
1.82, P-value = 0.036) after controlling for clinically important covariates. Neither
A1298C nor any MTHFR haplotype was associated with altered risk of relapse.
Inconsistent conclusions among different studies can be explained by many factors.
Differences in ethnic groups, drug doses, treatment protocols, gender ratios and age
are probably important.
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Regarding the role of MTHFR polymorphisms in the susceptibility to development of
childhood ALL, Franco, et al., (2001) determined the prevalence of C677T and
A1298C in 71 ALL patients and 71 matched control subjects. OR for ALL linked to
C677T was 0.4 (95% CI 0.2-0.8); for heterozygotes, it was 0.5 (95% CI 0.2-0.9) and
for homozygotes, it was 0.3 (95% CI 0.09-0.8). A1298C yielded an overall OR for
ALL of 1.3 (95% CI 0.7-2.6); for heterozygotes it was 1.3 (95% CI 0.7-7.6) and for
homozygotes it was 2.8 (95% CI 0.5-15.6). Thus Franco concluded that C677T was
linked to a significant 2.4-fold decreased risk of developing childhood ALL, whereas
A1298C did not affect the risk of ALL. In a later case-control study conducted by
Krajinovic (Krajinovic, et al., 2004a), 270 ALL patients and 300 healthy controls
were screened for C677T and A1298C polymorphisms. Two genotype combinations,
TT677AA1298 and CC677CC1298 were associated with reduced risk of ALL (OR =
0.4, 95% CI 0.2-0.9; OR = 0.3, 95% CI 0.1-0.6).
In summary, the polymorphism of C677T seems to be associated with a decreased
risk of developing childhood ALL. The known function of MTHFR in the folate
pathway is also consistent with this finding.
Reduced folate carrier (RFC)
Besides MTHFR, another important protein in the folate pathway is the reduced folate
carrier (RFC). RFC is involved in the primary route for membrane transport of
reduced folates in mammalian cells. Membrane transport via RFC is also an
important determinant of antifolate therapeutics used in cancer chemotherapy. It is
the major MTX transporter of which impaired function is recognised as a frequent
mechanism of drug resistance (Gorlick, et al., 1999) (Figure 1.8). Likewise, the loss
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of RFC function conceivably could contribute to disease states associated with
decreased accumulations of folate cofactors (Whetstine, et al., 2001).
The RFC gene located at chromosome 21q22.3 consists of 12 exons. To date, one
promoter region polymorphism, two non-synonymous polymorphisms in the coding
region and nine polymorphisms in the 3’ untranslated region have been described. Of
these, the G80A polymorphism which replaces histidine by arginine at position 80 has
been associated with an altered risk of neural tube defects (de Marco, et al., 2003).
The G-allele was also found to be correlated with lower plasma folate and higher
homocysteine levels in healthy persons (Chango, et al., 2000). Because folate and
homocysteine homeostasis are affected by MTX, it is possible that RFC G80A may
also modulate the outcome in patients in therapy.
Pharmacogenetic studies of RFC
There are only a few studies on the impact of RFC polymorphisms in childhood ALL.
Laverdiere, et al., (2002) assessed the association between the G80A polymorphism
and both MTX plasma levels and childhood ALL outcome in 204 patients. He found
that children with the G80A variant had worse EFS than patients with GG genotype
(P-value = 0.04); patients homozygous for A80 had higher plasma MTX levels (P-
value = 0.004) than other genotype groups. On the other hand, Kaufman, et al., (2003)
screened 246 ALL samples for RFC polymorphisms and only 3 were found to harbour
alterations in RFC gene. He concluded that RFC mutations were not common and did
not appear to play any significant role in intrinsic or acquired resistance to MTX in
childhood ALL.
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To further elucidate the influence of RFC polymorphisms on childhood ALL, more
studies are needed to enhance the understanding of in vivo pharmacokinetics that RFC
modulates.
1.2.2.3 Phase I and phase II enzymes
Phase I enzymes, such as cytochrome P450s, act on xenobiotics causing reactive
moieties to be formed while phase II enzymes, such as NAD(P)H:quinone
oxidoreductase 1 (NQO1) and glutathione-S-transferases (GSTs), are involved in the
neutralization of electrophilic compounds, enabling detoxification.
CYP1A1 and CYP2D6
Most xenobiotics, including many chemotherapeutic agents, will undergo the
activation by the cytochrome P450 enzyme system to activate their proposed
functions. The cytochrome P450 superfamily is responsible for the metabolism of
endogenous as well as exogenous compounds. The first 3 CYP families, CYP1,
CYP2 and CYP3, are responsible for 70-80% of all phase I dependent metabolism of
clinically used drugs (Bertz, et al., 1997) and participate in the metabolism of a huge
number of xenobiotics. Metabolic activation of procarcinogens and drugs may exert
carcinogenic or cytotoxic effects.
CYP1A1 plays a key role in phase I metabolism of polycyclic aromatic hydrocarbons
and in oestrogen metabolism (Masson, et al., 2005), while CYP2D6 is involved in the
metabolism of about 25% of prescribed drugs (Ingelman-Sundberg, 2002). Compared
with other members in P450 family, the CYP1A1 gene is relatively well conserved
probably due to the endogenous importance of the corresponding enzyme. Thus,
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polymorphisms that cause altered enzymatic function may produce significant impact
in body. CYP1A1*2A (T6235C) and *2B (A4889G and T6235C), with increased
activity and/or inducibility, are associated with a higher level of DNA adducts
formation and increased risk to certain types of carcinomas (Kato, et al., 1995;
Kawajiri, et al., 1993). The CYP2D6 gene is much more polymorphic, and shows
very good genotype-phenotype correlation when studied using debrisoquine as the
probe drug (Mahgoub, et al., 1977). The intronic mutation, CYP2D6*4 (G1934A),
affects the consensus acceptor splice site of the third intron and completely abolishes
the expression of the protein and activity, dramatically reducing the rate of substrate
metabolism.
Pharmacogenetic studies of CYP1A1 and CYP2D6
Although neither CYP1A1 nor CYP2D6 were thought to be directly involved in the
metabolism of chemotherapeutic agents used in ALL therapy, their impact on the
susceptibility to childhood ALL, as well as the risk of relapse, have been reported.
Sinnett, et al., (2000) carried out a case-control study in a French-Canadian
population and found that the frequency of individuals carrying the CYP1A1*2A
allele was significantly higher among patients (19.4%) as compared to controls
(11.7%), implicating an 80% increase in the risk of developing ALL associated with
*2A allele (OR = 1.8, 95% CI 1.1-3.1). Moreover, girls carrying at least one
CYP1A1*4 allele were significantly underrepresented in the ALL group (OR = 0.2,
95% CI 0.05-0.9), suggesting a gender-specific protective role against ALL for this
allele. However, the mechanism underlying this observation still remains unknown.
In the same study, the CYP2D6 polymorphism frequency did not vary between cases
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and controls. Krajinovic, et al., (2002a) evaluated 6 polymorphisms in CYP1A1,
CYP2D6 and CYP2E1 in 320 patients. Of these, 68 patients experienced an event,
defined as relapse or death from disease with a median follow-up of 58 months (2-84
months). He found that the presence of at least one CYP1A1*2A allele was
associated with an increased risk of leukaemia relapse (HR = 2.3, 95% CI 1.2-4.9);
neither CYP2D6*3 nor CYP2D6*4 influenced the treatment outcome.
Phase II enzymes conjugate hydrophilic molecules to the functional groups added by
phase I enzymes, causing detoxification and enhancing excretion of the inactivated
metabolites.
NAD(P)H:quinone oxidoreductase 1 (NQO1)
NAD(P)H:quinone oxidoreductase 1 reduces redox-cycling quinones to stable
hydroquinones, which can be readily conjugated by phase II enzymes and excreted, in
a single two-electron step. Another role for NQO1 in quinone detoxification is the
removal of potentially arylating quinones. Quinones can readily undergo addition and
substitution reactions and can react directly with protein thiols. The NQO1 gene
maps to 16q22.1 and is composed of 6 exons spanning 17,884 base pairs. Two
polymorphisms have been identified: NQO1*2 (C609T), which results in the absence
of enzyme function, and NQO1*3 (C465T), which causes diminished enzyme
function (Rubnitz, et al., 2003). The function of NQO1 suggests that patients with
decreased or null enzyme activity may be more susceptible to toxic and carcinogenic
effects of benzene and certain chemotherapeutic drugs.
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Pharmacogenetic studies of NQO1
Krajinovic, et al., (2002c) investigated whether 2 NQO1 polymorphisms, NQO1*2
and NQO1*3, modify the risk for childhood ALL in a case-control study involving
174 patients and 337 controls, both of French-Canadian origin. He found that the
children carrying at least one NQO1 mutant allele, either *2 or *3, were at increased
risk of developing ALL (OR = 1.7, 95% CI 1.2-2.4, P-value = 0.008). However,
Kracht, et al., (2002) genotyped 138 childhood ALL patients and 190 healthy
individuals for the NQO1*2 polymorphism, but did not observe significantly different
frequencies between the cases and controls. The author also suggested that their
findings might be representative only in their particular population.
The influence of NQO1 polymorphisms on the disease outcome was studied by
Krajinovic using the same sample set described above in the CYP genes section
(Krajinovic, et al., 2002a). NQO1*2 carriers were found to have shorter survival
probabilities using Kaplan-Meier analysis (P-value = 0.003). NQO1*2 retained its
predictive value in Cox regression analysis when other prognostic factors, including
age, gender, WBC count, immunophenotype, DNA index, risk stratification, treatment
protocol, and ethnicity, were taken into account (HR = 3.6, 95% CI 1.7-7.4). This
result suggested that NQO1*2 may independently influence the outcome of ALL.
Glutathione-S-transferases (GSTs)
The glutathione-S-transferases (GSTs) are grouped into 8 classes and detoxify a wide
range of cancer chemotherapeutic agents and environmental carcinogens. GSTP1 has
been found to catalyse the conjugation of glutathiones to its substrates, which protects
cells from alkylating agents and products of reactive oxidation. The GSTP1 gene
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localizes to chromosome 22q11.23 and is subject to polymorphisms. Unlike large
gene deletions in GSTM1 and GSTT1 genes, only point mutations were found in the
GSTP1 gene. GSTP1*B is a SNP that causes an isoleucine to valine substitution at
amino acid codon 105 (A105G). G105 occurs at a frequency of 33% in Caucasian
populations, and is associated with reduced enzyme activity (Marsh, et al., 2004).
Pharmacogenetic studies of GSTP1
Krajinovic, et al., (2002b) assessed the association of GSTP1 polymorphisms and the
susceptibility to childhood ALL by conducting a case-control study on 278 ALL
patients and 303 healthy controls, both of French-Canadian origin. He found that the
carriers of the GSTP1*B were associated with an increased risk of ALL (OR = 1.5,
95% CI 1.1-2.0), whereas the GSTP1*C was underrepresented in cases. The author
speculated that genetic variants of GSTP1 might contribute differently to the risk of
ALL probably because of distinct substrate specificities. Another study, conducted by
Zielinska, et al., (2004) achieved a consistent result: in a case-control study consisting
of 234 children at diagnosis of a childhood malignancy and 460 age- and sex-matched
healthy subjects, a significant increase in the frequency of GSTP1*B homozygous
mutation was detected in the children with neoplasms (OR = 5.7, 95% CI 2.4-13.8, P-
value ≤ 0.001).
As for the prognostic values of GSTP1 polymorphisms in childhood ALL, so far no
significant impact has been reported. Stanulla, et al., (2000) reported a study of 64
pairs of relapsed and non-relapsed patients drawn from the Berlin-Frankfurt-Munster
(BFM) protocols BFM-86 and BFM-90 ALL trials. Cases and controls were matched
on 7 criteria. GSTP1*B was not found to be significantly associated with the risk of
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relapse (OR = 0.33, 95% CI = 0.09-1.23, P-value = 0.099). In a study described in the
section above (Krajinovic, et al., 2002a), GSTP1 polymorphisms did not affect the
risk of relapse. Since the initial response to prednisone was found to be the strongest
predictor of therapy outcome in children with ALL treated according to BFM
protocols, Anderer, et al., (2000) assessed a potential association of phenotypically
relevant GST polymorphisms with prednisone response in childhood ALL by
conducting a case-control study of 45 prednisone poor-responders and 90 prednisone
good-responders who were matched according to initial WBC counts. They did not
find any association between GSTP1 genotypes and the response to prednisone.
Additional work on GSTP1 is warranted given the modest sample size studied.
1.2.2.4 Drug transporters
Multidrug resistance-1 (MDR1)
Unlike the enzymes that are directly involved in the structural modifications of their
substrates, drug transporters influence the effects of drugs by modulating their
pharmacokinetics. RFC, described earlier, is one example, but its function is limited
to the folate cycle. P-glycoprotein (P-gp) is a member of the adenosine triphosphate-
binding cassette (ABC) superfamily of membrane transporters. P-gp is involved in
the active transport of a great number of amphipathic molecules through lipid
membranes. The physiological role of P-gp is to against toxic xenobiotics by
pumping it out of the cell. However, as a wide range of important anticancer agents
can be actively extruded by this protein, P-gp expression in tumour cells maybe
associated with multidrug resistance phenotype. Anthracyclines, alkaloids and
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epipodophyllotoxins, which are used in the treatment of ALL, are P-gp substrates
(Ambudkar, et al., 1999).
The gene encoding for P-gp is known as the multidrug resistance-1 gene. To date, 29
SNPs have been identified in the entire human MDR1 gene (Marzolini, et al., 2004).
The C3435T in exon 26 is the first polymorphism for which pharmacologic
consequences were demonstrated (Hoffmeyer, et al., 2000). Many studies have
suggested the functional relevance of this silent polymorphism to mRNA, protein or
activity levels in a number of tissues (Jamroziak, et al., 2004). Therefore, it can be
speculated that polymorphic-based differences in P-gp expression may result in
varying exposure to environmental carcinogens, with lower activity linked to
increased risk of malignancy. Similarly, lymphoblasts with lower expression of P-gp
efflux pump may have higher intracellular drug levels and may respond better to
therapy.
Pharmacogenetic studies of MDR1
Despite numerous studies on SNPs in the MDR1 gene, no clear impact on the
pharmacokinetics and pharmacodynamics of drugs has emerged.
Effersh, et al., (2003) examined the common C3435T polymorphism in 20 T-ALL
cell lines and blood from 53 ALL patients and found no correlation between the
MDR1 genotype and mRNA expression, doxorubicin sensitivity of the cell lines, or
survival of patients. The author suggested that resistance resulting from acquired
mutations is more important than that arising from the constitutional polymorphism.
However, Jamroziak, et al., (2004) suggested that the MDR1 C3435T polymorphism
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might not only increase the susceptibility to developing childhood ALL but also
improve the clinical outcome. In his study, 113 children with ALL and 175 healthy
individuals of Polish Caucasian origin were screened for the C3435T polymorphism.
The TT3435 genotype was found to be associated with increased risk for development
of ALL (OR = 1.8, 95% CI 1.1-3.1, P-value = 0.037). On the outcome analyses,
CC3435 genotype carriers had significantly lower EFS probability (P-value = 0.007);
the Cox proportional hazards model-based analysis revealed that the HR for lower
EFS probability among CC homozygous subjects were 3.9 (P-value = 0.008). The
author concluded that while carriers of TT genotype were more at risk of developing
ALL, CC genotype carriers had a worse prognosis.
1.2.3 Statistical methods commonly used in the study of polymorphism-
disease association
Studies reporting DNA polymorphism-disease associations represent an important
source of information on disease gene candidacy. However, such studies are
extremely variable in terms of their design and of the statistical methodology
employed (Cooper, et al., 2002). To our best knowledge, there has not been a well
accepted guideline to standardise how an association investigation should be carried
out.
Despite the variability in data analyses, the statistical approaches described below are
commonly used, especially the studies in which only single, or a small number of,
polymorphisms are investigated. More information regarding the statistics in
epidemiology are summarised by Sahai and Khurshid (1996) and Dawson and Trapp
(2001).
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1.2.3.1 Hardy–Weinberg equilibrium test
Hardy–Weinberg equilibrium (HWE) is an expression of the notion of a population in
"genetic equilibrium" and is a basic principle of population genetics. It states that,
under certain conditions, after one generation of random mating, the genotype
frequencies at a single gene locus will become fixed at a particular equilibrium value.
It also specifies that those equilibrium frequencies can be represented as a simple
function of the allele frequencies at that locus.
Some original assumptions for HWE include:
 the organism under consideration is diploid, sexually reproducing, and has
discrete generations;
 ideally, mating within a single population is random and the population size is
infinite; and
 such a population experiences no selection, mutation or migration.
On theory, a Hardy-Weinberg population is static thus is used as a reference
population when discussing various factors.
Consider two alleles, A and a, with frequencies p and q, respectively, in the
population. The 3 possible genotype frequencies in the offspring will be: p2 for AA,
2pq for Aa and q2 for aa. These frequencies are called Hardy-Weinberg proportion.
For a certain locus in a studied population, an expected Hardy-Weinberg proportion
can be calculated based on the observed allele frequencies. If these observed
frequencies are significantly different from expected (significance test for deviation is
commonly carried out by chi-square test), the studied population is not in HWE.
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If a population control is used in a polymorphism-disease association study, the
control group must be validated by HWE test to demonstrate that there is no sampling
or genotyping bias. Therefore, HWE test is usually carried out prior to any other
statistical analyses.
1.2.3.2 Chi-square (χ2) test
Briefly, a chi-square test is a statistical approach used to evaluate whether there are
statistically significant differences between proportions for two or more groups in a
data set. It is probably the most common method for the data analyses in
epidemiological investigations.
There are various types of chi-square tests, among which Pearson's chi-square is the
original and most widely-used chi-square test. It is calculated by the formula:
n (Oi – Ei) 2
χ
2 = ∑ -------------
i=1 Ei
where:
 Oi = an observed frequency; and
 Ei = an expected (theoretical) frequency
In a polymorphism-disease association study, Oi and Ei are usually the frequencies of
mutant allele/genotype in cases and controls respectively. To conclude whether or not
the frequencies in two groups are significantly different needs the consultation of the
chi-square distribution table, which lists χ2 values and corresponding probability of
observing this difference under a specified degree of freedom.  If the calculated χ2
value is smaller than the conventional criteria for statistical significance, case and
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control groups have no difference on allele/genotype frequencies, or the
polymorphism is not associated with the status (with or without disease).
Nowadays, chi-square tests can be carried out in many computer or web-based
programs for free.
1.2.3.3 Z-test
The z-test is a statistical test used to determine if the difference between a sample
mean and the population mean is large enough to be statistically significant, or to
compare the proportions from two independent groups to determine if they are
significantly different from one another. It is assumed that the sample represents a
random sample of the relevant population and, if for the comparison of two
proportions, each group to be tested is independent of the other.
Z-test can be used to compare the frequencies of a particular allele in two populations.
The z-score of a two-proportion z-test (with equal variances) is calculated using the
formulas:
x1 x2 x1 + x2
P1 = ----- , P2 = ----- , P = ----------
n1 n2 n1 + n2
_________________
z = (P1 – P2)/√P(1 – P)(1/n1 + 1/n2)
where:
 x1, x2 = the observed number of studied allele in each population
 n1, n2 = the sample size of each population
 P1, P2 = the allele frequency in each population
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Finally, the z-score is compared to the cut-off values in the “Z table”, which will
indicate whether the observed difference of two allele frequencies is within the realm
of chance or it is statistically significant given a level of significance.
1.2.3.4 Fisher’s exact test
Although chi-square test is widely used in the literature, it should not be used when
the expected frequencies are small. In this situation, an alternative procedure called
Fisher’s exact test should be performed.
Fisher’s exact test is used to examine the significance of the association between two
variables in a 2 × 2 contingency table as below:
GROUP 1 GROU 2 TOTEL
CONDITION 1 A b a+b
CONDITION 1 C d c+d
TOTEL a+c b+d n = a+b+c+d




Assuming the given marginal totals, this formula gives the exact probability of
observing this particular arrangement of the data on the null hypothesis that the odds
ratio between Condition 1 and Condition 2 of Group 1 and Group 2 equals to 1 in the
sampling population. For Fisher’s exact test, the probability for each distribution of
frequencies more extreme than those observed must also be calculated, and added to
the probability of the observed set.
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Calculating Fisher’s exact test is nearly impracticable without a computer program.
Fortunately, nowadays this is no longer a problem in the research. Therefore,
although Fisher’s exact test is originally developed for the analysis where sample size
is small, many statisticians recommend that it should be used in all situations where a
2 × 2 contingency table is applicable.
1.2.3.5 Binary logistic regression
Binary logistic regression is a statistical regression model useful for situations in
which one wants to be able to predict the presence or absence of a characteristic or
outcome based on values of a set of predictor variables. It is suited to models where
the dependent variable is dichotomous, e.g., male or female, smoking or non-smoking.
One advantage of using binary logistic regression is that it requires no assumptions
about the distribution of the independent variables. Another is that the regression
coefficient can be interpreted in terms of odds ratios in case-control studies.
Therefore, binary logistic regression is extensively used in medical sciences.
Due to the great complexity, the mathematical basis for this approach will not be
elaborated. Like above methods, analysis using binary logistic regression is also
available in many statistical software packages.
1.2.3.6 Linkage disequilibrium (LD)
In population genetics, linkage disequilibrium (LD) is the non-random association of
alleles at two or more loci. LD describes a situation in which some combinations of
alleles or genetic markers occur more or less frequently in a population than would be
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expected from a random formation of haplotypes from alleles based on their
frequencies.
Suppose that two loci, A and B, with two alleles each are inspected. Each haplotype
frequency is denoted as: x11 for A1B1, x12 for A1B2, x21 for A2B1, x22 for A2B2. Then
each allele frequency will be:
Allele Frequency
A1 p1 = x11 + x12
A2 p2 = x21 + x22
B1 q1 = x11 + x21
B2 q2 = x12 + x22
According to the rules of elementary statistics, x11 equals to p1q1. A deviation of the
observed frequencies from the expected is referred to as the linkage disequilibrium
parameter, and is commonly denoted by a D: D = x11 – p1q1. The relationship among
the haplotype, allele frequencies and D can be summarized as:
A1 A2 Total
B1 x11 = p1q1 + D x11 = p2q1 – D q1
B2 x12 = p1q2 – D x11 = p2q2 + D q2
Total p1 p2 1
The value of D depends on the frequencies of the alleles inspected. There can be no
D observed if any locus has an allele frequency 0 or 1 and is maximal when
frequencies are 0.5. In addition, the normalized value of D, denoted as D’, is also
common in use:
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D’ = D / Dmax (if D ≥ 0)
D’ = D / Dmin (if D < 0)
where:
 Dmax is given by the smaller of p1q2 and p2q1, and
 Dmin is given by the larger of -p1q1 and -p2q2
Another measure of LD commonly reported with D' is the correlation coefficient
between pairs of loci, which is denoted as r:
r2 = D2 / p1p2q1q2
1.2.3.7 Receiver operating characteristic (ROC) curve
In signal detection theory, a receiver operating characteristic (ROC) curve is a
graphical plot of the sensitivity vs. (1 − specificity) for a binary classifier system as its
discrimination threshold is varied. The ROC can also be represented equivalently by
plotting the true positive rate (TPR) against the false positive rate (FPR). ROC curve
is also known as a Relative Operating Characteristic curve, as it is a comparison of
two operating characteristics, TPR and FPR, as the criterion changes. TPR
determines a classifier or a diagnostic test performance on classifying positive
instances correctly among all positive samples available during the test while FPR, on
the other hand, defines how many incorrect positive results occur among all negative
samples available during the test.
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Figure 1.10 The ROC space and plots of the four prediction examples.
An ROC space is defined by FPR and TPR as x- and y-axes respectively (Figure
1.10). Each prediction result represents one point in the ROC space. The best
possible prediction method would yield a point in the upper left corner or coordinate
(0, 1) of the ROC space, representing 100% sensitivity and 100% specificity. The (0,
1) point is also called a perfect classification. A completely random guess would give
a point along a diagonal line from the left bottom to the top right corners (e.g. point B
in Figure 1.10). The diagonal line divides the ROC space in areas of good or bad
classification. Points above the diagonal line indicate good classification results (e.g.
50
point A in Figure 1.10) while points below the line indicate wrong results (e.g. point
C in Figure 1.10). However, it’s notable that the prediction method can be simply
inverted to get points above the line (e.g. point C’ in Figure 1.10).
More details regarding the ROC curve as well as its applications can be found in
Fawcett’s article (Fawcett, 2005).
1.2.3.8 Some important terms in statistical analysis
To properly interpret the result of a statistical analysis, some statistical concepts must
be understood correctly, which are briefly introduced below.
P-value. In statistics, a result is called significant if it is unlikely to have occurred by
chance. Assuming the null hypothesis, the significance level of a test is the maximum
probability that the statistic would be observed. Hence, the significance level is the
probability that the null hypothesis will be rejected in error when it is true, a decision
known as a Type I error. The significance of a result is also called its p-value; the
smaller the p-value, the more significant the result is said to be. A popular level of
significance is 5%. If a calculated p-value is lower than 0.05, the difference is
considered as “statistically significant”, and interpreted as “there is only 1 chance in
20 that such a difference can occur by coincidence”.
Confidence interval (CI). Sometimes, instead of giving a simple point estimate,
investigators wish to indicate the variability the estimate would have in other samples.
To indicate this variability, interval estimates are used. Interval estimates are called
confidence intervals, which define an upper limit and a lower limit for a parameter
51
(e.g., mean, proportion, etc.) with an associated probability. The most often reported
confidence intervals in medical literatures are 95% CI.
Odds ratio (OR). It is defined as the ratio of the odds of an event occurring in one
group to the odds of it occurring in another group. If the probabilities of the event in
each of the groups are p (Group 1) and q (Group 2), then the odds ratio is:
p/(1-p) p(1-q)
OR = ---------- = ----------
q/(1-q) q(1-p)
An odds ratio of 1 indicates that the condition or event under study is equally likely in
both groups; an odds ratio greater than 1 indicates that the condition or event is more
likely in the Group 1; and an odds ratio less than 1 indicates that the condition or
event is less likely in the Group 1.
The 95% CI for a given OR is often provided when OR is calculated with a statistical
program. The algorithm, however, varies among different statistical methods. For a 2
× 2 contingency table in which the values are a, b, c and d respectively, the formula
for a 95% CI for the OR is:
___________________________
exp [ ln(OR) ± 1.96 × √(1/a + 1/b + 1/c + 1/d) ]
Statistical power. The power of a statistical test is the probability that the test will
reject a false null hypothesis, or in other words that it will not make a Type II error.
As power increases, the chances of a Type II error decrease, and vice versa. The
probability of a Type II error is referred to as β. Therefore power is equal to 1-β.
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Power analysis can either be before (a priori) or after (post hoc) data is collected. A
priori power analysis is conducted prior to the conducting of research and is typically
used to determine an appropriate sample size to achieve adequate power. Post-hoc
power analysis is conducted after a study has been conducted and uses the obtained
sample size and effect size to determine what the power was in the study assuming the
effect size in the sample size is equal to the population effect size.
Multiple comparisons. In statistics, the problem of multiple comparisons occurs when
one subjects a number of independent observations to the same acceptance criterion
that would be used when considering a single event. When statistical tests are used
repeatedly, the chance of Type I error will increase as the number of comparisons
increases. The experiment-wide significance level α is estimated by the formula:
α = 1-(1-α per comparison) number of comparisons
In order to retain the same overall rate of false positives in a test involving multiple
comparisons, the standards for each comparison must be more stringent. A common
solution is to set a smaller α for each comparison, e.g., Bonferroni correction.
However, such an adjustment has proven to be overly conservative, as it will raise the
proportion of false negatives, thus failing to identify real significant differences in the
data.
As for the polymorphism-disease association study, it is still under debate whether
multiple comparisons are allowed in epidemiological investigations, in which
situation the corrections for multiple comparisons should be applied, and how to




1.3.1 Screening β-thalassaemia mutations using APEX methodology
In Section 1.1, the various methodologies to diagnose β-thalassaemia has been
reviewed. By integrating the high accuracy of minisequencing methodology and the
great multiplexing capacity of DNA chip technology, arrayed primer extension
(APEX) may be a desirable strategy for genotyping purpose.
Although APEX principle has been successfully performed in previous works, the
number of targets that can be simultaneously detected in those applications are small.
In addition, all mutations screened are only common in the Mediterranean countries.
So far, an APEX-based DNA chip suitable for the diagnosis of common β-
thalassaemia mutations in Southeast Asia is not available. One of the aims of this
thesis is to describe the development of a DNA chip based on the APEX principle,
and its application to screen common Southeast Asian β-thalassaemia mutations. We
planned to:
1. Design and troubleshoot APEX primers for 33 mutations in 2 separate genes
(24 are in β-globin gene while the other 9 are in TPMT gene), including the
nucleotide substitutions, insertions and small deletions;
2. Simplify and optimise a previous protocol (Kurg, et al., 2000) of DNA chip
preparation;
3. Evaluate the accuracy of the APEX strategy by conducting a blinded
validation using 200 genomic DNA samples;
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4. Standardise the genotype assignment by establishing the quantitative criteria
for the assignment of positive, negative or inconclusive results on each
interrogating spot on the DNA chip.
The work presented in this thesis may provide useful information for the design and
preparation of an APEX-based genotyping assay to screen known point mutations of
any other genes.
1.3.2 Pharmacogenetic profiling of children with ALL using AsPEX
strategy
In Section 1.2, some xenobiotics-metabolising genes and their common
polymorphisms have been described; previous studies with regards to their roles in
pharmacogenetics of childhood ALL have also been reviewed.
It is clear that childhood ALL is a highly heterogeneous disease with at least 7
different subtypes (Yeoh, et al., 2002) and that both genetic and environmental factors
are involved, so that a single genetic variation is unlikely to be the sole cause for the
development of this disease. The use of multiple drug combinations that are
metabolized by different genes suggests that the mechanisms behind the different
drug response or treatment outcome will be complicated. This necessitates
simultaneous investigation of multiple polymorphisms in various genes to ensure a
comprehensive pharmacogenetic profile of a patient with childhood ALL to help
provide a more intelligent drug choice and dosing. Moreover, racial differences of the
frequencies of polymorphisms in metabolising genes can be interrogated.
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Appropriate population studies controlling for differences in ethnicity are crucial for
pharmacogenetic studies.
Due to various reasons such as technical difficulties to perform multiplex detection,
sample availability, or assay cost, most of previously reported work focused on a
small number of polymorphisms, usually no more than 5. Most genetic variants had
to be laboriously screened individually due to diverse genotyping methods and very
different laboratory conditions. An allele-specific primer extension (AsPEX) strategy
was designed for genotyping in my project due to several considerations:
 cyclic amplification of fluorescent signal is applicable in this methodology
while in APEX, it is not;
 double-stranded PCR products can be directly used as DNA templates in
AsPEX, hence generation of single-stranded DNA templates is avoided;
 only 1 fluorescent label is required and genotyping can be done by a single
chip;
The technical details will be described in Chapter 2 and Chapter 4.
Unlike the numerous reports in Caucasians, pharmacogenetic studies in childhood
ALL in Asian populations are not well studied. It remains unclear whether the
conclusions from the investigations done in Caucasian populations are relevant as a
guide for our local research and the clinical applications. Therefore, we proposed to
conduct a comprehensive genotyping project to simultaneously screen 14
polymorphisms in 8 important genes described in the previous context: TPMT
(G460A, A539T, and A719G), MTHFR (C677T and A1298C), RFC (G80A),
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CYP1A1 (C4887A, A4889G and T6235C), CYP2D6 (G1934A and A4887 deletion),
GSTP1 (A105G), NQO1 (C609T) and MDR1 (C3435T). We aimed to:
1. Design and validate a DNA chip-based genotyping strategy, which is based on
the principle of single nucleotide allele-specific primer extension (AsPEX)
and capable of simultaneously detecting all 14 polymorphisms of interest;
2. Report allele frequencies of those polymorphisms in our local multi-racial
population mainly consisting of Chinese, Malay and Indian;
3. Perform a case-control study using a large number of childhood ALL patient
DNA samples and cord blood DNA from healthy newborns, to study the roles
of those polymorphisms in the susceptibility to childhood ALL;
4. Investigate the impact of these 14 polymorphisms on the risk of relapse in
childhood ALL.
Allele frequencies reported in this thesis may be informative for other research on
these polymorphisms.
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Chapter 2 Materials and Methods
In this chapter, the materials and methods used in the two projects will be described.
The first section will cover the development and validation of APEX-based DNA chip,
followed by the details regarding the design and application of the AsPEX genotyping
strategy.
2.1 APEX genotyping platform for β-globin and TPMT genes
2.1.1 APEX methodology
Figure 2.1 The flowchart of APEX methodology.
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2.1.2 DNA samples
Genotyping assays were carried out using anonymised DNA samples from 75
newborns carrying β-thalassaemia mutations and another 125 subjects randomly
selected for TPMT mutation screening. Of these 125 subjects, 70 were children with
ALL while the other 55 were healthy newborns. These 200 samples, which had been
genotyped using ARMS-PCR or PCR-RFLP before, were used for validation of the
APEX genotyping technology. The operator was, however, blinded to their genotypes
in the experiments.
For the carriers of β-thalassaemia mutations and healthy newborns, 5-10 mL cord
blood samples were collected in EDTA tubes and stored at -80 °C. For the children
with ALL, 1-3 mL bone marrow samples were obtained by aspiration performed from
the posterior superior iliac spine. Samples were collected using EDTA or sodium
heparin tubes and stored at -80 °C. Genomic DNA was extracted from stored cord
blood or bone marrow using standard phenol-chloroform methodology (Sambrook
and Russell, 2001) and was stored at -80 °C. DNA concentrations and A260/A280
ratios were measured using standard UV spectrophotometer. A DNA sample was
considered eligible if its concentration was higher than 50 ng/µL and A260/A280
ratio was between 1.6 and 2.0.
The research protocol was approved by the university’s Institutional Review Board,
and informed consents were obtained from all participating individuals and/or their




PCR primer pairs were designed to first amplify the sequences spanning the 23 and 9
mutation sites in the β-globin and TPMT genes respectively. Single-stranded
oligonucleotides, rather than normal double-stranded DNA, were used as templates in
the hybridisation process, as suggested by previous study (Guo, et al., 1994). To
synthesise the single-stranded DNA templates, we performed a second round of PCR
using one primer of each primer pair to amplify either the sense or the antisense
strand. Primer sequences for PCR amplification are summarized in Table 2.1. All
primer sequences were designed using Oligo® 6 software (Molecular Biology Insight,
Inc. USA). Amplification was carried out in a reaction mixture of 50 μL containing
0.4 μmol/L of each primer, 200 μmol/L of each dNTP, 1.5 mmol/L Mg2+ and 1.5 units
of AmpliTaq Gold® polymerase in 1× supplied GeneAmp® 10× PCR Gold Buffer
(Applied Biosystems, USA). In the first PCR, 250ng genomic DNA was used as the
templates. Five microliters of PCR products from the first round was used for the
second PCR reaction.
Each exon of both genes were amplified separately using the same PCR protocol
consisting of an initial pre-warming step at 95 ºC for 10 min, followed by 35 cycles of
incubations at 94 ºC for 60 s, 55 ºC for 30 s and 72 ºC for 30 s, and a final extension
at 72 ºC for 5 min in TouchDown™ thermal cycler (Hybaid Limited, UK). After the
second round of amplification, single-stranded PCR products from the respective
DNA samples were pooled together, precipitated by isopropanol, and finally
resuspended in 10 μL Tris-EDTA. This pooled sample was stored at -20 ºC until
further use.
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Table 2.1 PCR primers for the amplification of [a] β-globin and [b] TPMT genes.
Primers in bold letters were used in the second PCR to synthesise single-stranded
DNA. F: forward primer; R: reverse primer.
[a]




-29 (A→G); -28 (A→C); CAP+1 (A→C); Initiation Codon 
(T→G); Codon 8/9 (+G); Codon 14/15 (+G); Codon 15
(G→A); Codon 17 (A→T); Codon 19 (A→G); Codon 26 
(G→T); Codon 27 (G→T); Codon 27/28 (+C); Codon 30 




IVSI 110 (G→A); Codon 35 (C→A); Codon 39 (C→T); 



























Intron-exon Junction (G→A); G644A; T681G; A719G
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2.1.4 APEX primers
The APEX primers were designed to anneal to the DNA region immediately adjacent
to the polymorphic sites to be interrogated. For those primers used to detect
substitutions, their 3’ ends were terminated at the nucleotides upstream of the
mutations; for those used to detect insertions or deletions, the 3’ ends stopped at the
nucleotide just before the insertion or deletion. To allow for using a universal
hybridisation condition, all primers were designed to possess similar Tm values of
about 70 ºC. An oligo(dT)15 spacer with amino modification on N-terminal was
added to the 5’ end of each primer. The primer sequences were shown in Table 2.2.
All primers were analysed and modified using Oligo® 6 to avoid secondary structure
formation at 3’ ends, which might cause false positive results. A mismatch nucleotide
was introduced to destabilize strong hairpin or dimer formations to reduce non-
specific primer extension.
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Table 2.2 APEX primers for [a] β-globin and [b] TPMT genes. An oligo(dT)15
spacer with an amino-modification was added to each primer at its 5’ end. Codon 27


























IVSII 654 GAATAACAGTGATAATTTCTGGGTTAAGG 3
1 T is a mismatched nucleotide;
2 The spacer for Codon 39 is TTTTTACAGCATTTT;













4 APEX primer for T146C was designed to hybridise with the antisense strand.
2.1.5 Microarray preparation
APEX primers were diluted in ArrayIt™ Micro Spotting Solution Plus (TeleChem
International, Inc., USA) at a final concentration of 20 μmol/L. Primers were loaded
in a 384-well microtitre plate and spotted onto CSS-100 Silylated Slides (CEL
Associates, Inc., USA) by contact printing using a ProSys 5510A instrument
(Cartesian Technologies, Inc., USA). Primers were coupled to the slide surface by
forming covalent bonds between amino residues and Schiff base aldehyde after
incubating spotted slides in a humid chamber at 37 ºC overnight. Using the High-
Throughput Wash Station (TeleChem International, Inc., USA) mounted on a
magnetic stirrer, slides after incubation were washed in 0.2% sodium dodecyl
sulphate (SDS) for 2 min, sodium borohydride reducing solution (dissolved 1.0 g
sodium borohydride (Sigma-Aldrich, Inc., USA) in 300 mL phosphate buffered saline
(PBS) and then added to 100 mL 100% ethanol) for 10 min, 0.2% SDS again for 2
min and double distilled water for a simple rinse. Processed slides were dried by
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centrifugation in the Microarray High Speed Centrifuge (TeleChem International, Inc.,
USA) and stored at 4 ºC until further use.
2.1.6 Chip layout
Thirty-two APEX primers for 23 and 9 different polymorphisms in the β-globin and
TPMT genes respectively were integrated on a chip to form a genotyping array. This
array was replicated 4 times to screen all the mutations for 1 sample. In addition, the
slide was partitioned into 4 areas so that a set of two chips could genotype up to 4
samples simultaneously (Figure 2.2).
Figure 2.2 Chip layout (APEX). Black and yellow circles refer to mutations in
TPMT and β-globin genes respectively. One genotyping area consisting of 4 small
replicated arrays (green) is dedicated for hybridisation of 1 sample.
2.1.7 Hybridisation
One microliter of single-stranded DNA amplified from each of the β-globin gene and
of TPMT gene fragments were mixed and diluted in 8 μL UniHyb™ Hybridisation
Solution (TeleChem International, Inc., USA). Five microliters of pooled template
per array was used for hybridisation on a set of two chips. Small glass cover slips
were used to diminish evaporation. The slides were sealed in the ArrayIt™
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Hybridisation Cassette (TeleChem International, Inc., USA) and placed in a 60 ºC
water bath for 2 hrs. They were then washed in 0.2% SDS, 1×SSC (150 mmol/L
NaCl, 15 mmol/L Na Citrate, pH7.0) for 2 min, followed by another 2 min wash in
2×SSC and a simple rinse in ddH2O. Drying was carried out by centrifugation. The
hybridized DNA can be used to perform APEX reaction immediately, or stored at 4
ºC until further use.
2.1.8 APEX reactions
Two ddNTP mixtures, “AG” and “CU”, were prepared beforehand: “AG” consisted
of Cy3 labelled ddATP, Cy5 labelled ddGTP (PerkinElmer Life Sciences, Inc., USA),
unlabelled ddCTP and ddTTP at 0.04 μmol/L of each; “CU” contained Cy3-ddCTP,
Cy5-ddUTP (PerkinElmer Life Sciences, Inc., USA), unlabelled ddATP and ddGTP
at 0.02 μmol/L of each. Fifty microliters of APEX reaction mixture, containing 1 μL
(2 units) Thermo Sequenase™ DNA polymerase (Amersham Biosciences Ltd, USA),
5 μL supplied reaction buffer, 1 μL “AG” ddNTP mixture, and 43 μL ddH2O, was
loaded onto one of two previously hybridized slides in a set. A similar mixture
containing “CU” instead of “AG” was loaded onto the other slide. Cover slips were
used to prevent evaporation. Chips were sealed in Hybridisation Cassettes and placed
in a 60 ºC water bath for 10 min. Then the slides were washed in a solution of 10
mmol/L Tris-HCl, 0.2 mol/L NaCl, 1 mmol/L EDTA and 0.1% Tween 20 for 2 min,
followed by 2 min wash in 0.1 mol/L NaOH and a simple rinse in ddH2O. The slides




Fluorescent signals were detected in a ScanArray® 5000 scanning instrument with the
ScanArray® 3.1 (Packard BioScience Ltd, UK) using the following excitation
wavelengths: 543 nm for Cy3 and 633 nm for Cy5. Both the laser power and the
photo-multiplier tube gain were kept constant at 95%. The chips were scanned at a
speed of 5 μm/s, and the images were saved in TIFF format for future analyses of
signal intensities.
2.1.10 Signal intensity analysis
The acquired images were analysed using QuantArray® software 3.0 (Packard
BioScience Ltd, UK). Signal intensities from all spots within the genotyping array
were measured and adjusted by deducting the average background intensities around
the spots. The signal-to-noise ratio was calculated using the formula:
Signal intensity – Background intensity
Ratio = ------------------------------------------------
Background intensity
In order to distinguish the signal from the noise quantitatively, we obtained the signal-
to-noise ratio data from 50 samples with validated genotypes (25 screened for β-
thalassaemia mutations and 25 screened for TPMT gene polymorphisms). The
intensity ratios were randomly assigned to a training set (two thirds of data) or a
validation set (one third of data). The ratios in the training set were analysed by a
receiver operating characteristic (ROC) curve to determine an appropriate cut-off
value. This value was subjected to the validation in the other data set to evaluate its
accuracy.
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2.1.11 Tests on unbalanced PCR amplification
To test the efficacy of generating ssDNA for APEX reaction using PCR with
unbalanced primers, 100 ng starting materials and the primer pair described in
Section 2.1.3 were used. PCR amplifications were carried out using the same
protocol except for final primer concentrations: 1) 0.5 μmol/L forward primer and 2)
0.5 μmol/L forward primer plus 0.05 μmol/L reverse primer (10:1). There were 4
replicates under each condition. PCR products were precipitated by 80% isopropanol
and resuspended in 50 μL double-distilled H2O respectively. ssDNA concentrations
were measured and calculated using standard UV spectrophotometer. Comparison
was performed using both independent t-test and Mann-Whitney test, SPSS version
10 (SPSS Inc., USA) at 5% level of significance.
2.2 AsPEX genotyping strategy for pharmacogenetic profiling
2.2.1 Study design
A total of 334 cord blood DNA from healthy newborns (129 Chinese, 104 Malay and
101 Indian), and 225 childhood ALL patient DNA samples (135 Chinese, 72 Malay
and 18 Indian) were screened for 14 polymorphisms in 8 genes, as described earlier in
Section 1.2.2: TPMT (G460A, A539T, and A719G), MTHFR (C677T and A1298C),
RFC (G80A), CYP1A1 (C4887A, A4889G and T6235C), CYP2D6 (G1934A and
A4887 deletion), GSTP1 (A105G), NQO1 (C609T) and MDR1 (C3435T). The
methods of sample collection, processing and DNA extraction were described in early
Section 2.1.2.
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Patient samples were collected between 1992 and 2005, and patients’ characteristics
are listed in Table 2.3. Patients who were below 1 year old were diagnosed as
“infantile ALL”. When both the sample at diagnosis and the sample in remission
were available from the same patient, only the sample at diagnosis was used for
genotyping.
The research protocol was approved by local Institutional Review Board, and
informed consents were obtained from all participating individuals and/or their
parents.
Table 2.3 The characteristics of patients with childhood ALL.


























Frequencies of the respective polymorphisms in each population were determined
based on the genotypes in controls. To investigate the roles of those polymorphisms
in the susceptibility to developing childhood ALL, a case-control study for all three
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races was conducted; however, Indians were excluded in the statistical analyses due to
the small number (n = 18) in the patient group.
To study the impact of polymorphisms on the risk of ALL relapse, we recruited 98 out
of those 225 patients based on 2 criteria: 1) patients were treated on NUH, HK-SG or
MA-SPORE protocol; 2) they were either in complete remission (CR) or had relapse.
CR is defined as the status that no event such as death or relapse occurs within 24
months after the start of therapy. The remaining was either patients treated on other
protocols or their clinical status had not been determined by the time of the study.
However, among the 98 cases, 1 CR and 3 relapsed patients did not have complete
genotype information for all studied loci thus they were excluded in multivariate
analyses. Finally 69 patients in CR and 25 relapsed patients were enrolled in this
study.
2.2.2 Genotyping strategy
Instead of using respective PCR-RFLP test to detect each polymorphism in individual
assay, which was time-consuming, laborious and even costly, we developed a
genotyping system integrating single nucleotide AsPEX reaction and DNA chip
technology, to screen DNA samples for all 14 polymorphisms simultaneously.
For each polymorphism, two homogeneous AsPEX primers that only differed at their
3’ terminals are fully matched to wild-type and mutant sequences respectively. Wild-
type or mutant querying primers of all polymorphisms are pooled to make two primer
mixes. In terms of the choice of labeling reagent, we tested the feasibility of using
fluorescence-labelled ddNTPs as an alternative of fluorescence-labelled dNTPs which
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were used previously (Chan, et al., 2004). Two multiplex single nucleotide AsPEX
reactions are carried out with two primer mixes respectively, in the presence of DNA
templates, polymerase and TAMRA-labelled ddNTPs. A primer is supposed to be
incorporated with a particular TAMRA-ddNTP only in the circumstance that the
primer is fully matched with the template. Products after AsPEX reaction are
subsequently loaded on a DNA chip and hybridized with its respective
complementary oligonucleotide tags. The fluorescent pattern emitted by the labelled
primers revealed genotypes in the imaging system. The genotyping strategy and the
principle of AsPEX are illustrated in Figure 2.3.
Figure 2.3 [a] The genotyping strategy and [b] the principle of AsPEX.
[a] The flowchart of AsPEX methodology
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[b] The principle of AsPEX. Each polymorphic locus is queried by a pair of AsPEX
primers. Homozygosity will display a single fluorescent spot while heterozygosity
will display two fluorescent spots.
2.2.3 Multiplex PCRs and purification
PCR primer pairs were designed to amplify the sequences carrying the
polymorphisms in respective genes. Primers were analysed in Oligo® 6 (Molecular
Biology Insight, Inc. USA) to optimise sequence structures and avoid false
amplification of the counterparts in pseudogenes. Three multiplex and one single
PCR reactions were carried out using the same protocol consisting of an initial pre-
warming step at 95 ºC for 4 min, followed by 35 cycles of incubations at 95 ºC for 60
s, 55 ºC for 30 s and 72 ºC for 30 s, and a final extension at 72 ºC for 5 min.
Components in PCR reaction mixes as well as the information of all primers are
summarized in Table 2.4.
After PCR amplifications, products from three multiplex reactions and one single
reaction were pooled together and purified using QIAquick® PCR Purification Kit
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(QIAGEN GmbH, Germany) according to the protocol provided by the manufacturer.
Purified DNA was ready to use for subsequent reaction or stored at -20 ºC until
further use.















Multiplex PCR 500 250/each 1.5 0.5/each 0.2 30
Single PCR 200 100/each 1.5 0.5/each 0.1 30
* 10 × PCR buffer and ddH2O are not listed; the compositions of primer mix are summarized in [b].
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[b]











































* F, forward primer; R, reverse primer.
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2.2.4 Multiplex single nucleotide AsPEX
AsPEX primer pair for each polymorphism was designed using Oligo® 6. Two
AsPEX primer mixes, labelled as “Wild-type” or “Mutant”, were made by mixing
corresponding primers at various concentrations. Each tag sequence was
complementary to corresponding AsPEX primer. The sequence structure analyses
using free program SBEprimer (version 1.1, available on http://www.zaik.uni-
koeln.de/AFS/Projects/Bioinformatics/sbeprimer.html) showed that all tags were free
of hairpin structures and would not form non-specific hybrids with other AsPEX
primers at 37 ºC or above. Primer sequences and their respective concentration in
reaction mixes are summarized in Table 2.5. Cyclic multiplex single nucleotide
AsPEX was carried out using the protocol consisting of an initial pre-warming step at
95 ºC for 3 min, followed by 60 cycles of incubations at 95 ºC for 20 s and 60 ºC for
20 s. Thermo Sequenase™ DNA polymerase (Amersham Biosciences Ltd, USA) was
used to catalyse the incorporation of TAMRA-ddNTP. The components in the
reaction mix are also listed in Table 2.5. After the reaction, 5 μL Hybridisation
Buffer (18×SSC, 3×TE) were immediately added into 10 μL products to prevent side
reactions. The products were then ready to use for subsequent hybridisation or stored
at 4 ºC for further use.
Table 2.5 [a] Components in AsPEX reaction, [b] information of AsPEX primers and












Multiplex AsPEX 100~200 1.0 1.0 0.25 10
* 10 × Reaction buffer and ddH2O are not listed;
1 10 × TAMRA-ddNTP Mix consists of 0.20 μmol/L ddATP, 0.15 μmol/L ddCTP, 0.50 μmol/L ddGTP and 0.20
μmol/L ddUTP;
2 Compositions of primer mix and respective concentration of each primer in the reaction are summarized in [b].
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[b]
AsPEX Primer 1 (5’ – 3’) Queried Polymorphism Concentration 2 (nmol/L)
TTTGACATGATTTGGGATAGAGGAG(A) TPMT G460A 25 nmol/L
ATCATAAGAAAGAACACACAGGAGAT(A) TPMT A539T 25 / 50 nmol/L
ATTGACTGTCTTTTTGAAAAGTTATA(G) TPMT A719G 50 nmol/L
CCCAATGCTATATGTCAGTTGAGG(A) NQO1 C609T 50 nmol/L
AAGCTGCGTGATGATGAAATCGG(A) MTHFR C677T 25 nmol/L
GGAGCTGACCAGTGAAGA(C) MTHFR A1298C 25 nmol/L
AAGCGGAAGTGTATCGGTGAGAC(A) CYP1A1 C4887A 25 nmol/L
AAGACCTCCCAGCGGGCAAT(C) CYP1A1 A4889G 25 / 50 nmol/L
TGTTTCACTGTAACCTCCACCTCCT(C) CYP1A1 T6235C 50 nmol/L
CTTACCCGCATCTCCCACCCCCAG(A) CYP2D6 G1934A 50 nmol/L
GATGAGCTGCTAACTGAGCACA(G) CYP2D6 A2637 deletion 50 nmol/L
AGTTGGTGTAGATGAGGGAGAT(C) GSTP1 A105G 25 nmol/L
CCTCCTTTGCTGCCCTCACG(A) MDR1 C3435T 50 nmol/L
AAGCAAAGGTAGCACACGAGGC(T) RFC G80A 50 / 25 nmol/L
1 Sequences listed were AsPEX primers for the detection of wild-types; primers for mutant genotypes only
differed at the 3’ end nucleotides, which were indicated in the parentheses;
2 Concentrations presented in the table were those in the 10 × primer mix. If not specified, concentrations were
the same for two primers in a pair; otherwise, the first concentration was that of the primer for wild-type while the
second was the concentration of the primer for mutant genotype.
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[c]
Queried Polymorphism Complementary Tag (5’ – 3’) Oligonucleotide Spacer (5’ – 3’)
TPMT G460A TCCTCTATCCCAAATCATGTCAAA AAAAAAAAAAAAAAAA--amino
TPMT A539T TCTCCTGTGTGTTCTTTCTTATGAT TTTTTTTTTTTTTTT--amino
TPMT A719G ATAACTTTTCAAAAAGACAGTCAAT AAAAAAAAAAAAAAA--amino
NQO1 C609T CTCAACTGACATATAGCATTGGG CATTTTTTTTTTTTTTT--amino
MTHFR C677T CGATTTCATCATCACGCAGCAT TTCTTTTTTTTTTTTTTT--amino
MTHFR A1298C CTTCACTGGTCAGCTCCTCC CCCCTTTTTTTTTTTTTTTT--amino
CYP1A1 C4887A TCTCACCGATACACTTCCGCTT GCCTTTTTTTTTTTTTTT--amino
CYP1A1 A4889G TTGCCCGCTGGGAGGTCTTT CTCTTTTTTTTTTTTTTTTT--amino
CYP1A1 T6235C GGAGGTGGAGGTTACAGTGAAACA AAAAAAAAAAAAAAAA--amino
CYP2D6 G1934A TGGGGGTGGGAGATGCGGGTAAG GGAAAAAAAAAAAAAAA--amino
CYP2D6 A2637 deletion GTGCTCAGTTAGCAGCTCATC CAGCCTTTTTTTTTTTTTT--amino
GSTP1 A105G TCTCCCTCATCTACACCAACT ATCTTTTTTTTTTTTTTTT--amino
MDR1 C3435T GTGAGGGCAGCAAAGGAGGCCAACA AAAAAAAAAAAAAAA--amino
RFC G80A CCTCGTGTGCTACCTTTGCTTCTAC TTTTTTTTTTTTTTT--amino
* Each complementary tag was linked to an oligonucleotide spacer at its 3’ end; all spacers possessed amino-
modifications at their 3’ ends.
2.2.5 Chip layout and preparation
One chip was designed to simultaneously screen 2 DNA samples for those 14
polymorphisms. Two identical panels were assigned to one sample, one for wild-type
and the other for mutant genotype. Within each panel, there were 4 replicated arrays,
of which the purpose was to provide redundant signals to ensure reproducibility and
internal validation. The layout of the chip is illustrated in Figure 2.4.
Oligonucleotide tags that were complementary to primers used for AsPEX reaction
were diluted in ArrayIt™ Micro Spotting Solution Plus (TeleChem International, Inc.,
USA) at a final concentration of 20 μmol/L. Tags were loaded in a 384-well
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microtitre plate and spotted onto CSS-100 Silylated Slides (CEL Associates, Inc.,
USA) by contact printing using a ProSys 5510A instrument (Cartesian Technologies
Inc., USA). Primers were coupled to the slide surface by forming covalent bonds
between amino residues and Schiff base aldehyde after incubating spotted slides in a
humid chamber at 37 ºC overnight. Using the High-Throughput Wash Station
(TeleChem International, Inc., USA) mounted on a magnetic stirrer, slides after
incubation were washed in 0.2% SDS for 3 min, sodium borohydride reducing
solution (dissolved 1.0 g sodium borohydride (Sigma-Aldrich, Inc., USA) in 300 mL
PBS and then added to 100 mL 100% ethanol) for 10 min, 0.2% SDS again for 3 min
and double distilled water for a simple rinse. The slides were dried by centrifugation
in the Microarray High Speed Centrifuge (TeleChem International, Inc., USA) and
stored at 4 ºC until further use.
Figure 2.4 Chip layout (AsPEX). The slide is partitioned into 4 panels, each of which
consists of 4 replicated arrays (blue). Two panels are used for genotyping 1 sample,
thus a single chip is able to genotype 2 different samples simultaneously.
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2.2.6 Hybridisation
Five microlitres of AsPEX products (mixed with hybridisation buffer) were loaded
onto the panel on DNA chip for hybridisation. Small glass cover slips were used to
reduce evaporation. The chip was sealed in the ArrayIt™ Hybridisation Cassette
(TeleChem) and placed in a 50 ºC water bath for 2 hrs. They were then washed in
2×SSC for 3 min, followed by another 3 min wash in 1×SSC and a simple rinse in
ddH2O. Drying was carried out by centrifugation. The hybridized chip was ready for
signal detection or could be stored at 4 ºC.
2.2.7 Fluorescence detection and analysis
Fluorescent signals were detected in a ScanArray® 5000 scanning instrument with the
ScanArray® software 3.1 (Packard BioScience Ltd, UK) using 543 nm excitation
wavelengths for TAMRA. Both the laser power and the photo-multiplier tube gain
were kept constant at 95%. The chips were scanned at a speed of 5 μm/s, and the
images were saved in BMP format for future analyses of signal intensities.
The acquired images were analysed using QuantArray® 3.0 (Packard BioScience Ltd,
UK). Signal intensities were adjusted by deducting the average background
intensities around the spots.
In order to determine the genotype quantitatively, we randomly selected 15-20
samples (if available) of each genotype for each polymorphism and analysed their
fluorescent intensities (log2-transformed) in a ROC curve. A cut-off value was
selected and evaluated using the strategy described in the Section 2.1.10.
79
2.2.8 Statistical analyses
Hardy-Weinberg equilibrium (HWE) was tested using free web-based HWE
calculator (available on http://www.genes.org.uk/software/hardy-weinberg.shtml) for
each polymorphism in Chinese, Malays and Indians controls respectively. Testing
deviation from the HWE was performed using Pearson's chi-square (χ2) test, using the
observed genotype frequencies obtained from the control group and the expected
genotype frequencies estimated by Hardy-Weinberg proportions. The 5%
significance level was adopted and its value under 1 degree of freedom was 3.84.
Any polymorphism, of which the χ2 > 3.84, was excluded from subsequent analyses in
the respective ethnic group.
The linkage disequilibrium was evaluated using the web-based program, “SNPStats”
(available at http://bioinfo.iconcologia.net/index.php?module=Snpstats). Values of D,
D’ and r were reported.
Two-proportion z-test (2-sided) was used to examine the differences of allelic
frequencies among Chinese, Malay and Indian populations (web-based calculator
available at http://www.dimensionresearch.com/resources/calculators/ztest.html). The
level of significance was set at 5%.
The post hoc statistical power analyses were performed using the program “PS”
(Dupont and Plummer, 1998) when studying the risk of developing childhood ALL in
Chinese and Malays. Based on the actual control/case ratio, observed allele
frequencies and odds ratio (OR), desired sample size was calculated for each studied
locus given the 5% significant level and 80% statistical power.
80
Fisher’s exact test (2-sided) was used to investigate the diversities of genotype
distributions between ALL cases and population controls. The level of significance
was set at 5%. The odds ratio was given with 95% confidence intervals (CI).
Considering the fact that some polymorphisms were within the same gene, e.g.,
MTHFR C677T and A1298C, and that some genes were involved in related metabolic
pathways, e.g. MTHFR and RFC, we also analysed the distributions of combined
genotypes between cases and controls for selected polymorphism pairs using Fisher’s
exact test (2-sided). Again, the level of significance was set at 5% and OR with 95%
CI was given. The strategy used to analysed combined genotypes was adopted from
previous publications (Krajinovic, et al., 2002c, 2004a) with slight modifications.
Binary logistic regression analyses were performed to model the risk of ALL relapse
including dichotomous genotypes of selected polymorphisms with or without
clinically important covariates, i.e. gender, age, ethnic group and treatment protocol.
The type of variable entry method was “Enter”, which included all variables in the
regression model. Two stepwise methods, “Forward: LR” and “Backward: LR”, were
also tested. Odds ratios with 95% CI were calculated and the level of statistical
significance was set at 5%.
Fisher’s exact test and binary logistic regression analysis were performed using SPSS
version 10 (SPSS Inc., USA). P-values, odds ratios and their 95% CI were calculated
by the program. If not specified, p-value adjustment for multiple comparisons was
not applied in the presentation of the results.
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2.2.9 Sensitivity comparison between APEX and AsPEX
To compare the sensitivity between APEX and AsPEX, a test was carried out using a
serial of dilution of target DNA. The primer pair for TPMT A719G in Table 2.4b
was used to generate and purify the DNA template using the protocol described in
Section 2.2.3. APEX and AsPEX assays were conducted respectively using a series
of starting materials, no-template-control, 25 ng, 50 ng, 100 ng and 200 ng, according
to the protocols described in early sections except that only TAMRA-ddUTP were
used in reaction mix. Signal intensity was measured for 4 replicates and for A-allele
only. Comparison was performed using both independent t-test and Mann-Whitney
test, SPSS version 10 (SPSS Inc., USA). The level of significance was set at 5%.
2.2.10 Test on potential extension biases of AsPEX primers terminated
with different nucleotides
In order to test whether there were extension biases for AsPEX primers terminated
with different nucleotides, we carried out individual AsPEX assay for each
polymorphism using one sample with known heterozygous genotype (CYP2D6
A2637del was excluded since no polymorphism was found in our study). PCR
protocol was described in Table 2.4a (“Single PCR”) and all paired primers were in
2.5 nmol/L each in AsPEX reaction. The assays were conducted in the procedure
described in Section 2.2.3 to Section 2.2.7. Comparisons were performed using both
independent t-test and Mann-Whitney test, SPSS version 10 (SPSS Inc., USA). The
level of significance was set at 5%.
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Chapter 3 Results
Similar to Chapter 2, this current chapter is divided into 2 sections, summarizing the
experimental data and analyses in the two projects respectively. The first part will
present the results on the APEX genotyping strategy followed by the AsPEX
methodology.
3.1 APEX genotyping platform for β-globin and TPMT genes
3.1.1 PCR amplifications
All genomic DNA extracted from cord blood or bone marrow met the minimal quality
requirements, i.e., ≥ 50 ng/µL and A260/A280 ratio between 1.6 and 2.0.
The electrophoretic result of PCR reactions to amplify sequences carrying
polymorphic loci in β-globin and TPMT genes is shown in Figure 3.1. The designed
fragment sizes are 283bp, 266bp and 209bp for 3 amplicons of β-globin gene
respectively, and 247bp, 240bp, 268bp, 244bp and 248bp for 5 amplicons of TPMT
gene respectively. The electrophoresis demonstrated that the sizes of all PCR
amplicons were consistent with their respective designs and no anonymous DNA
band was observed, indicating that PCR amplifications were specific. Correct
amplification is the premise for the reliability of subsequent APEX reaction using
these PCR products as the templates.
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Figure 3.1 Electrophoretic result. The fragment sizes of the DNA ladder are shown
on the left; the sizes of amplicons are shown at the bottom. Lane 1-3: exon 1/2/3 in
the β-globin gene respectively; Lane 4: DNA ladder; Lane 5-9: exon 4/5/7/8/10 in the
TPMT gene respectively.
3.1.2 APEX reactions
Before starting to simultaneously screen β-globin and TPMT genes for interested
polymorphisms, we first investigated whether there was cross-hybridisation or false
primer extension in APEX reaction. We separately loaded each single-strand DNA
template on the DNA chip to test the specificity of in situ hybridisation. Negative
control containing no DNA templates but other reactants was also tested. The result
of this preliminary experiment is shown in Figure 3.2. It shows that all APEX
primers gave correct fluorescent signals from the respective loci except for the
negative control (data not shown). Neither cross-hybridisation nor false primer
extension was observed, indicating that the APEX strategy is reliable.
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[a] Dark circles: TPMT mutations; yellow circles: β-thalassaemia mutations
[b]
[c]
Figure 3.2 Investigation for potential cross-hybridisation and false primer extension.
Nucleotides that each fluorescence represent are indicated below. [a] Array layout; [b]
TPMT gene templates alone; and [c] β-globin gene templates alone.
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Figure 3.3 demonstrates some examples of genotyping results using APEX DNA chip.
An example of wild-type sample carrying no mutations in both the β-globin and the
TPMT genes is shown in [b]. Only the fluorescence representing wild-type
nucleotides were observed on the DNA chip. The four images illustrated in [c]
display the fluorescence representing mutant genotypes. Compared with
corresponding wild-type patterns shown in [b], it was easy to distinguish those
mutations in the images. The results shown in [c] also demonstrate the feasibility of
simultaneously screening 2 different genes for polymorphisms.
Figure 3.3 Detection of polymorphisms in β-globin and TPMT genes using APEX
DNA chip. [a] Array layout. [b] The fluorescence indicating wild-type genotypes for
all loci queried. Because antisense strands were used as templates in APEX reaction,
fluorescence for T146C and IVSII 654 (C→T) indicated complementary nucleotides
respectively. [c] The fluorescence indicating mutations in the β-globin and TPMT
genes respectively. The images are picked out from different tests. Mutations are
highlighted by arrows and their names and nucleotide changes are given below.





We evaluated the accuracy of the APEX genotyping system using a set of 200
genomic DNA samples with known genotypes. Table 3.1 lists all polymorphisms
that have been detected in our evaluation. There was 100% concordance in the TPMT
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genotyping results using the APEX platform and conventional genotyping
methodologies. In the 75 β-thalassaemia patient samples, correct genotypes were
obtained in 73 (97.3%) except: a sample carrying a 619bp deletion which was
inapplicable to our chip; and another sample carrying a heterozygous Codon 8/9
insertion which was wrongly reported as a wild-type due to the weak fluorescent
signal on its mutant allele. The error on Codon 8/9 was rectified by repeating the test
on a new sample aliquot. The polymorphisms that have been successfully detected by
the APEX DNA chip include nearly all common β-thalassaemia and TPMT mutations
found in Southeast Asia area, indicating that this new genotyping technique has great
potential for local clinical diagnosis.
Table 3.1 Summary of the number of the mutations detected in the 200 test DNA
samples (75 for genotyping β-thalassaemia mutations while 125 for genotyping
TPMT mutations). Only heterozygous mutations have been found in the test.






















3.1.4 Analyses of fluorescence intensity
The first 50 samples (25 screened for β-thalassaemia and 25 screened for TPMT
deficiency) with completed genotyping results were selected for signal intensity
analysis and validation. Figure 3.4 illustrates the average intensity ratios of true
signals from selected samples. The fluorescent signal indicating the correct
nucleotide at the respective locus could be easily distinguished from the false signal
including the background noise and non-specific fluorescence.
Figure 3.4 Comparison of the average ratios of the fluorescence intensity between
true signals and false signals. “A”, “C”, “G”, “T” and “Blank” refer to 4 types of
nucleotides and negative control respectively. For the 2 wild-types ([a] and [c]),
respective average ratios were from 40 replicates of 10 different samples screened in
independent assays; as for the 2 heterozygous ([b] and [d]), data were from 16
replicates of 4 different samples screened in independent assays.
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In order to determine the real signal quantitatively, we randomly split the intensity
data into a training set and a validation set. The data in the training set were
analysed using ROC curve (Figure 3.5).
Figure 3.5 Signal intensity (APEX) analysis in the training set using a ROC curve.
Only the area satisfying Sensitivity ≥ 0.70 and (1 − Specificity) ≤ 0.3 is displayed.
The area under the curve is 0.995 (SE = 0.001, asymptotic 95% CI 0.992-0.998),
representing the probability that the assay result for a randomly chosen positive case
will exceed the result for a randomly chosen negative case. The asymptotic
significance is < 0.001, which means that using the assay is far superior to guessing or
by chance.
Based on the ROC curve which demonstrates the sensitivity and specificity under
various criteria, two cut-off values were selected: 5.0 and 10.0. The former
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corresponds to approximately 97% TPR (or about 97% of all real signals will be
correctly identified) and 5% FPR (or about 5% of all noise will be wrongly considered
as real signals); the latter corresponds to approximately 90% TPR and 0.5% FPR. We
subsequently applied the cut-off values to the validation set. The (TPR, FPR) values
for 5.0 and 10.0 are (97%, 4%) and (87%, 0.6%) respectively.
3.1.5 Efficacy testing on unbalanced PCR amplification to generate ssDNA
To test whether PCR with a primer pair in unbalanced concentrations was more
efficient to generate ssDNA than PCR with a single primer, ssDNA yields were
compared by amplifying 100 ng starting materials using two strategies respectively.
The results were shown in Table 3.2. Although slightly more yields were obtained by
unbalanced PCR amplification, the difference did not achieve statistical significance
in independent t-test (P-value = 0.302). Analysis using non-parametric Mann-
Whitney test showed no statistical significance (P-value = 0.561), either. Two
strategies appeared to have similar efficacy to generate ssDNA templates according to
this comparison.
Table 3.2 Comparison of ssDNA yields using single primer and unbalanced primer
pair in PCR amplification. [Condition 1] 0.5 μmol/L forward primer; [Condition 2]
0.5 μmol/L forward primer plus 0.05 μmol/L reverse primer.
Concentration (ng/μL) 95% CI
Condition
1 2 3 4
Mean difference P-value (2-tailed)
Lower Upper
1 411 408 437 430
2 427 427 431 434
-8.25 0.302 -26.12 9.62
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3.2 AsPEX genotyping strategy for pharmacogenetic profiling
3.2.1 PCR amplifications
All genomic DNA extracted from cord blood or bone marrow met the minimal quality
requirements, i.e., ≥ 50 ng/µL and A260/A280 ratio between 1.6 and 2.0.
DNA sequences carrying 14 polymorphisms were amplified in 3 multiplex and 1
single PCR reactions using the same protocol. Figure 3.6 shows the size of each
amplicon in individual amplification. The electrophoresis demonstrated that the sizes
of all PCR amplicons were consistent with their respective design. No nonspecific
DNA band was observed, indicating that PCR amplifications were highly accurate
and specific. However, due to the similar fragment sizes, products of multiplex PCR
were unable to be directly checked using the electrophoresis in agarose gel.
Figure 3.6 The sizes (unit: bp) of amplicons carrying polymorphic loci queried. The
fragment sizes of the DNA ladder are shown on two sides; the sizes of amplicons are
shown at the bottom. Lane 1/15: DNA ladders; Lane 2: RFC; Lane 3: MDR1; Lane 4:
GSTP1; Lane 5/6: CYP2D6; Lane 7/8: CYP1A1; Lane 9/10: MTHFR; Lane 11:
NQO1; Lane 12/13/14: TPMT.
3.2.2 Multiplex AsPEX reaction
In the preliminary experiment, negative control containing all reactants except for the
purified DNA templates was tested for possible false fluorescent signals. The result
showed no false signals for all queried loci (Figure 3.7b), indicating that there was no
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primer-primer interaction causing non-specific nucleotide extension in this multiplex
reaction. Then we could proceed to conduct our genotyping assays in ALL patients
and controls. Images in Figure 3.7 demonstrate the genotyping results using AsPEX
strategy.
To validate this new genotyping methodology, we randomly picked out a few samples
and screened them for the polymorphisms using conventional PCR-RFLP tests. This
cross-validation showed that, for the polymorphic loci tested in our study, multiplex
AsPEX for simultaneous detection of all 14 polymorphisms could achieve
competitive accuracy compared with individual PCR-RFLP test on each locus. On an
average over 98% concordance was acquired between genotypes obtained by DNA
chip and those obtained by PCR-RFLP, indicating that multiplex AsPEX is a reliable
method for genotyping purpose. The summary of respective polymorphism frequency
will be presented in later section.
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Figure 3.7 Detection of 14 polymorphisms in 8 xenobiotics-metabolising genes using
multiplex AsPEX methodology. The wild-type panel is shown on the left while the
mutant panel is on the right. For a queried position, the fluorescence on wild-type and
mutant panel indicates whether the DNA sequence carries the mutation: single
fluorescence represents wild-type or homozygous variant; heterozygous genotype
displays fluorescence on both panels. Variants are highlighted by arrows and their
names are given below each image; some genotypes may appear in several images but
only their first appearances are highlighted.
[a] Array layout
[b] Negative control showing absence of false positive
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[c] NQO1 CT609 (Row 1, Column 4), CYP1A1 CC6235 (Row 2, Column 3), GSTP1
AG105 (Row 2, Column 4), CYP2D6 AA1934 (Row 3, Column 1), MTHFR AC1298
(Row 3, Column 4), MDR1 TT3435 (Row 4, Column 1)
[d] CYP1A1 GG4889 (Row 2, Column 2), MDR1 CT3435 (Row 4, Column 1), RFC
GA80 (Row 4, Column 2)
[e] CYP2D6 GA1934 (Row 3, Column 1), RFC AA80 (Row 4, Column 2)
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[f] NQO1 TT609 (Row 1, Column 4)
[g] TPMT GA460 (Row 1, Column 1), TPMT AG719 (Row 1, Column 3), GSTP1
GG105 (Row 2, Column 4)
[h] CYP1A1 TC6235 (Row 2, Column 3), MTHFR CT677 (Row 3, Column 3),
MTHFR CC1298 (Row 3, Column 4)
96
[i] TPMT AT539 (Row 1, Column 2), CYP1A1 AG4889 (Row 2, Column 2)
[j] CYP1A1 CA4887 (Row 2, Column 1), MTHFR TT677 (Row 3, Column 3)
3.2.3 Analyses of fluorescence intensity
In order to demonstrate the power of our method in the discrimination among wild-
type, heterozygous and homozygous mutations, we randomly selected 15-20 positive
samples (if available) of each genotype for each polymorphism, measured the
fluorescent intensities at particular locus, and compared them with negative controls.
Figure 3.8 is the summary of our intensity analyses, and shows clear distinctions
among negative control, heterozygous and homozygous genotypes at each
polymorphic locus tested (with some exceptions due to missing genotypes).
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Figure 3.8 Analyses of fluorescence intensity. Intensity values are log2-transformed
and labelled on the x- and y-axis. Homozygous variations were not identified for a
































































































































































































































































































































































As described in Section 2.2.7, Chapter 2, we split the intensity data into a training set
and a validation set to determine and verify the cut-off values, with which genotype
class would be assigned quantitatively. Log2-transformed intensity values were used
to generate a ROC curve and the TPR vs. FPR are displayed (Figure 3.9). The area
under the curve is approximately 1.000 (SE = 0, asymptotic 95% CI 0.999-1.000), and
the asymptotic significance is < 0.001.
Two cut-off values, 5.08 and 5.63 corresponding to (100%, 1.8%) and (95.9%, 0)
(TPR, FPR) respectively, were selected. When these two cut-off values were applied
to the validation set, the (TPR, FPR) for 5.08 and 5.63 are (99.6%, 3.0%) and (97.9%,
0.5%) respectively.
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Figure 3.9 Signal intensity (AsPEX) analysis in the training set using a ROC curve.
Only the area satisfying Sensitivity ≥ 0.95 and (1 − Specificity) ≤ 0.05 is displayed.
3.2.4 Genotype/allele frequencies of polymorphisms in Chinese, Malay and
Indian populations
Using our chip-based genotyping system, we screened 334 cord blood DNA samples
from healthy newborns (129 Chinese, 104 Malay and 101 Indian) and 225 DNA
samples from patients with childhood ALL (135 Chinese, 72 Malay and 18 Indian) for
those 14 polymorphisms described earlier. The genotype frequencies of those
polymorphisms in a specific ethnic group are summarized in Table 3.3a. All
genotype distributions of population controls were validated for Hardy-Weinberg
equilibrium (HWE) (Table 3.3b). However, the genotype distributions of CYP1A1
T6235C and RFC G80A in the Chinese were shown to deviate significantly from
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Hardy-Weinberg expectations. Therefore, the genotypic frequencies of these two loci
in the population control of the Chinese were excluded from subsequent analyses.
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Table 3.3 Respective genotype frequencies of 14 polymorphisms in controls and
patients with childhood ALL. Missing genotypes were not counted in. [a] Genotype
frequencies; [b] Results of HWE tests for population controls.
[a]
Population Controls Childhood ALL CasesPolymorphic
Loci
Genotype
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2 P-value χ2 P-value χ2 P-value
TPMT G460A N/A # N/A 0 0.959
TPMT A539T N/A N/A N/A
TPMT A719G 0 0.965 0.06 0.802 0.07 0.791
NQO1 C609T 0.18 0.672 0.25 0.619 0.68 0.411
MTHFR C677T 0.73 0.393 2.95 0.086 1.36 0.244
MTHFR A1298C 0.23 0.630 0.68 0.410 0 0.980
CYP1A1 C4887A N/A N/A 0.01 0.921 0.07 0.799
CYP1A1 A4889G 2.53 0.111 0.04 0.839 1.52 0.217
CYP1A1 T6235C 8.54 0.003 1.01 0.314 0.30 0.582
CYP2D6 G1934A N/A 0.07 0.796 0.01 0.910
CYP2D6 A2637del N/A N/A N/A
GSTP1 A105G 1.62 0.203 0.06 0.799 0.14 0.705
MDR1 C3435T 0.54 0.463 0.02 0.895 0.05 0.822
RFC G80A 5.85 0.016 1.66 0.197 1.74 0.187
# N/A, not applicable. HWE test was inapplicable when only one genotype was detected.
In order to investigate whether the allele frequencies at a particular polymorphic locus
were diverse among different ethnic groups, we compared Chinese, Malay and Indian
populations using two-proportion z-test (2-sided). The results which showed
statistical significances (5% level of significance) are summarized in Table 3.4.
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Table 3.4 Comparing allele frequencies among the 3 ethnic groups: Chinese, Malays
and Indians. Only the polymorphic loci which demonstrated statistically significant






C 114 (44.2%) 134 (64.4%)
NQO1 C609T
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MTHFR C677T
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MTHFR C677T







A 198 (76.7%) 124 (61.4%)
MTHFR A1298C








C 256 (100%) 197 (97.5%)
CYP1A1 C4887A







A 183 (72.6%) 169 (83.7%)
CYP1A1 A4889G







T 109 (52.4%) 126 (62.4%)
CYP1A1 T6235C







G 256 (100%) 191 (97.4%)
CYP2D6 G1934A







G 256 (100%) 181 (90.5%)
CYP2D6 G1934A







G 191 (97.4%) 181 (90.5%)
CYP2D6 G1934A








C 156 (63.9%) 95 (47.5%)
MDR1 C3435T







C 124 (60.2%) 95 (47.5%)
MDR1 C3435T







G 88 (42.7%) 118 (59.0%)
RFC G80A
A 118 (57.3%) 82 (41.0%)
0.001
3.2.5 Individual polymorphisms and the risk of developing childhood ALL
Since the protein products of some genes in our study are involved in the metabolism
of carcinogens, or participate in the pathways of detoxification, it is rational to
speculate that polymorphisms in these genes may alter the risk of developing
childhood ALL. To test this hypothesis, we compared the genotype distributions of
each polymorphic locus between patients with childhood ALL and population
controls using Fisher’s exact test. The analyses that demonstrated statistically
significant differences (5% significance level) are summarized in Table 3.5. T-
lineage ALL was analysed together with B-lineage ALL; gender effect was not
considered in analyses due to the unavailability of sex information for the control
group. Ethnic stratification was performed in all analyses; and due to the small
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number of Indian children with ALL (n = 18), they were excluded from statistical
analyses.
Table 3.5 Genotype distributions of the polymorphisms associated with the risk of
developing childhood ALL in [a] Chinese and in [b] Malays. The results of post hoc
power analyses are summarized in [c]. P1, crude p-value without the correction for
multiple comparisons; P2, adjusted p-value after Bonferroni correction; N/A, not
applicable.
[a]
Polymorphic Loci Genotype ALL Cases Controls OR (95% CI) P1 P2
CC 39 (29.1%) 24 (18.6%) 1 (reference) N/A
CT 69 (51.5%) 66 (51.2%) 0.644 (0.350-1.185) 0.170 0.510
TT 26 (19.4%) 39 (30.2%) 0.410 (0.202-0.835) 0.014 0.042
NQO1 C609T
CT+TT 95 (70.9%) 105 (81.4%) 0.557 (0.330-0.994) 0.060 0.180
CC 74 (55.2%) 55 (42.6%) 1 (reference) N/A
CT 52 (38.8%) 55 (42.6%) 0.703 (0.420-1.176) 0.192 0.576
TT 8 ( 6.0%) 19 (14.8%) 0.313 (0.128-0.767) 0.011 0.033
MTHFR C677T
CT+TT 60 (44.8%) 74 (57.4%) 0.603 (0.370-0.981) 0.049 0.147
[b]
Polymorphic Loci Genotype ALL Cases Controls OR (95% CI) P1 P2
CC 60 (85.7%) 74 (71.2%) 1 (reference) N/A
CT 10 (14.3%) 30 (28.8%) 0.411 (0.186-0.908) 0.028 N/A
TT 0 0 N/A N/A
MTHFR C677T
CT+TT 10 (14.3%) 30 (28.8%) 0.411 (0.186-0.908) 0.028 N/A
GG 26 (36.6%) 22 (21.4%) 1 (reference) N/A
GA 34 (47.9%) 44 (42.7%) 0.654 (0.317-1.348) 0.274 0.822
AA 11 (15.5%) 37 (35.9%) 0.252 (0.104-0.607) 0.003 0.009
RFC G80A




Polymorphic Locus Actual Size




(number / ratio / OR)
Desired Size
(number)
TPMT G460A 270 / 0.956 / N/A N/A 144 / 1.444 / N/A N/A
TPMT A539T 270 / 0.956 / N/A N/A 144 / 1.444 / N/A N/A
TPMT A719G 270 / 0.956 / 5.841 702 144 / 1.444 / 1.160 24346
NQO1 C609T 268 / 0.963 / 0.652 370 142 / 1.465 / 0.925 9695
MTHFR C677T 268 / 0.963 / 0.615 341 140 / 1.486 / 0.456 265
MTHFR A1298C 270 / 0.956 / 1.068 20585 144 / 1.444 / 1.161 2770
CYP1A1 C4887A 270 / 0.948 / N/A N/A 144 / 1.431 / 1.437 8910
CYP1A1 A4889G 270 / 0.933 / 1.020 208112 144 / 1.444 / 1.289 1184
CYP1A1 T6235C 270 / 0.956 / N/A N/A 142 / 1.465 / 1.012 372636
CYP2D6 G1934A 268 / 0.955 / N/A N/A 144 / 1.361 / 1.952 948
CYP2D6 A2637del 266 / 0.962 / N/A N/A 142 / 1.310 / N/A N/A
GSTP1 A105G 270 / 0.956 / 0.840 3345 144 / 1.444 / 1.003 8208403
MDR1 C3435T 258 / 0.953 / 1.133 4448 140 / 1.471 / 1.168 2293
RFC G80A 266 / 0.917 / N/A N/A 142 / 1.451 / 0.525 139
* The actual/desired sample size is represented by the total number of alleles in ALL cases as well as the
control/case ratio.
In Chinese, the homozygous TT genotype at position 609 in NQO1 gene is found to
be significantly associated with a decreased risk of developing childhood ALL (OR =
0.410, 95% CI 0.202-0.835, P-value = 0.014). In combination of both CT and TT
genotypes, the association seems to remain unchanged although the P-value is no
longer significant (OR = 0.557, 95% CI 0.330-0.994, P-value = 0.060). The
heterozygous CT genotype alone does not show any impact on the susceptibility to
childhood ALL in our analysis.
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C677T polymorphism in the MTHFR gene is found to be associated with a decreased
risk of developing childhood ALL in both Chinese and Malays. In Chinese, the
homozygous TT genotype at MTHFR C677T locus shows statistically significant
different distributions between ALL cases and population controls (OR = 0.313, 95%
CI 0.128-0.767, P-value = 0.011), indicating that this genotype is associated with a
decreased risk of childhood ALL; however, heterozygous CT677 does not show any
impact on the risk. In Malays, CT677 is found to be associated with a decreased risk
of ALL (OR = 0.411, 95% CI 0.186-0.908, P-value = 0.028) while no MTHFR TT677
has been detected.
As the observed genotype distribution of RFC gene was not in agreement with the
Hardy-Weinberg equilibrium in the Chinese controls, this polymorphism was
analysed in Malays only. The AA genotype is found to be strongly associated with a
decreased risk (OR = 0.252, 95% CI 0.104-0.607, P-value = 0.003), and this
association still remains significant when AA and GA genotypes are analysed as a
single pooled category (OR = 0.470, 95% CI 0.239-0.923, P-value = 0.038).
However, the GA genotype alone demonstrates no impact on the risk in Malays (OR
= 0.654, 95% CI 0.317-1.348, P-value = 0.274).
Our analyses show that the impact of individual polymorphism on the disease
susceptibility varied in the different ethnic groups. However, it should be noted that
some results will no longer achieve statistical significance if Bonferroni correction is
applied.
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3.2.6 Combined genotypes and the risk of developing childhood ALL
Since there are 2 studied polymorphisms, C677T and A1298C, in MTHFR gene, we
next investigated their combined effect, which have been previously studied in other
populations (Skibola, et al., 1999; Krajinovic, et al., 2004a). In addition, as we have
found in the univariant analyses that 2 polymorphisms in Chinese (i.e., MTHFR
C677T and NQO1 C609T) and 2 in Malays (i.e., MTHFR C677T and RFC G80A) are
associated with a reduced risk of developing childhood ALL, we were interested to
see how their combined genotypes would impact on the risk of developing ALL. The
results obtained by Fisher’s exact tests are summarized in Table 3.6 and Table 3.7 for
Chinese and Malays respectively.
Table 3.6 Distributions of combined genotypes in the ALL cases and controls of
Chinese population. Combinations that were not detected are not shown. P1, crude p-
value without the correction for multiple comparisons; P2, adjusted p-value after
Bonferroni correction; N/A, not applicable.
[a]
MTHFR C677T MTHFR A1298C ALL Cases Controls OR (95% CI) P1 P2
CC AA 31 (23.1%) 15 (11.6%) 1 (reference) N/A
CT AA 35 (26.1%) 41 (31.8%) 0.413 (0.192-0.887) 0.025 0.125
TT AA 8 ( 6.0%) 19 (14.7%) 0.204 (0.073-0.571) 0.003 0.015
CC AC 37 (27.6%) 34 (26.4%) 0.527 (0.243-1.140) 0.126 0.630
CT AC 17 (12.7%) 14 (10.8%) 0.588 (0.230-1.502) 0.339 1.000
CC CC 6 ( 4.5%) 6 ( 4.6%) 0.484 (0.133-1.755) 0.320 1.000
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[b]
NQO1 C609T MTHFR C677T ALL Cases Controls OR (95% CI) P1 P2
CC CC 18 (13.4%) 6 ( 4.7%) 1 (reference) N/A
CT CC 43 (32.1%) 32 (24.8%) 0.448 (0.160-1.256) 0.151 1.000
TT CC 13 ( 9.7%) 17 (13.2%) 0.255 (0.079-0.823) 0.027 0.216
CC CT 19 (14.2%) 10 ( 7.8%) 0.633 (0.191-2.103) 0.554 1.000
CT CT 22 (16.4%) 26 (20.2%) 0.282 (0.095-0.834) 0.024 0.192
TT CT 10 ( 7.5%) 19 (14.7%) 0.175 (0.053-0.582) 0.005 0.040
CC TT 2 ( 1.5%) 8 ( 6.2%) 0.083 (0.014-0.506) 0.006 0.048
CT TT 4 ( 3.0%) 8 ( 6.2%) 0.167 (0.037-0.758) 0.029 0.232
TT TT 3 ( 2.2%) 3 ( 2.3%) 0.333 (0.053-2.116) 0.329 1.000
Table 3.7 Distributions of combined genotypes in the ALL cases and controls of
Malay population. Combinations that were not detected are not shown. P1, crude p-
value without the correction for multiple comparisons; P2, adjusted p-value after
Bonferroni correction; N/A, not applicable.
[a]
MTHFR C677T MTHFR A1298C ALL Cases Controls OR (95% CI) P1 P2
CC AA 21 (30.0%) 31 (29.8%) 1 (reference) N/A
CT AA 6 ( 8.6%) 22 (21.1%) 0.403 (0.140-1.161) 0.136 0.544
CC AC 34 (48.6%) 32 (30.8%) 1.568 (0.752-3.270) 0.267 1.000
CT AC 4 ( 5.7%) 8 ( 7.7%) 0.738 (0.197-2.768) 0.751 1.000
CC CC 5 ( 7.1%) 11 (10.6%) 0.671 (0.203-2.213) 0.570 1.000
[b]
MTHFR C677T RFC G80A ALL Cases Controls OR (95% CI) P1 P2
CC GG 22 (31.9%) 17 (16.5%) 1 (reference) N/A
CT GG 4 ( 5.8%) 5 ( 4.8%) 0.618 (0.144-2.660) 0.713 1.000
CC GA 29 (42.0%) 31 (30.1%) 0.723 (0.321-1.626) 0.538 1.000
CT GA 5 ( 7.2%) 13 (12.6%) 0.297 (0.089-0.997) 0.052 0.260
CC AA 8 (11.6%) 25 (24.3%) 0.247 (0.089-0.684) 0.008 0.040
CT AA 1 ( 1.4%) 12 (24.3%) 0.064 (0.008-0.545) 0.003 0.015
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We observed that some combined genotypes appear to enhance their associations with
the susceptibility of developing ALL compared with individual effects.
In the Chinese cohort, MTHFR A1298T wild-type (AA) seems to strengthen the
protective effect of MTHFR C677T variant (either CT or TT genotype) (Table 3.6a).
CT677 genotype is able to achieve statistical significance when AA1298 is taken into
account (OR = 0.413, 95% CI 0.192-0.887, P-value = 0.025) while this association is
not significant when this polymorphism is considered individually (OR = 0.644, 95%
CI 0.350-1.185, P-value = 0.170). As for TT677, which is found to be statistically
significant individually, its association with the risk of developing ALL appears
stronger if combined with AA1298 (OR = 0.204, 95% CI 0.073-0.571, P-value =
0.003). And the significance still remains after Bonferroni correction is applied
(adjusted p-value = 0.015). Furthermore, in terms of the joint effect of NQO1 C609T
and MTHFR C677T, five combined genotypes are found to be associated with
reduced risk of developing ALL. Two of them, TT609/CT677 and CC609/TT677,
may have strong impact on the ALL susceptibility (adjusted p-value = 0.040 and
0.048 respectively).
In Malays, MTHFR C677T is no longer associated with the risk of developing ALL if
A1298C locus is taken into account (Table 3.7a). Interestingly, the analyses on the
joint effect of MTHFR C677T and RFC G80A revealed that RFC AA80 is in a strong
association with the risk of developing ALL independent of MTHFR C677T
polymorphism (Table 3.7b). Both CC677/AA80 and CT677/AA80 are shown to be
statistically significant even with Bonferroni correction (for CC677/AA80, OR =
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0.247, 95% CI 0.089-0.684, adjusted p-value = 0.040; for CT677/AA80, OR = 0.064,
95% CI 0.008-0.545, adjusted p-value = 0.015).
In addition, we measured the LD between the two studied loci, 677 and 1298, in the
MTHFR gene. The respective values of D, D’ and r in Chinese/Malays are: -0.073/-
0.037, 0.999/0.999 and -0.373/-0.248.
3.2.7 Polymorphisms and the risk of ALL relapse
As described in Section 1.2.2.2, Chapter 1, MTHFR is directly involved in the
metabolism of chemotherapeutic agents used for the treatment of childhood ALL;
MDR1 and RFC is able to alter the pharmacodynamics and pharmacokinetics of the
drugs; functions of NQO1 and GSTP1 are relevant to the drug toxicities. In addition,
although CYP1A1 does not have known functions in the metabolism of drugs treating
leukaemia, indirect effect from this enzyme cannot be exempted. Therefore, it was
rational to speculate that dysfunctions of those gene products, caused by the
polymorphisms, might modify the drug effects and consequently influence the
treatment outcome. To test this speculation, we investigated the impact of those
polymorphisms on the risk of ALL relapse using binary logistic regression model with
or without patients’ clinical characteristics (Table 3.8).
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Table 3.8 The impact of genetic polymorphisms on the risk of relapse in children
with ALL [a] with or [b] without non-genetic factors. The first feature of each class
was used as the reference group. The data entry method was “Enter”. OR1 and P1
were calculated by Fisher’s exact test; OR2 and P2 were adjusted p-values calculated






OR1 (95% CI) P1 OR2 (95% CI) P2
Gender
M 17 (68.0%) 37 (53.6%) Reference Reference
F 8 (32.0%) 32 (46.4%) 0.544 (0.207-1.427) 0.245 0.172 (0.045-0.667) 0.011
Age at Diagnosis
< 1 1 ( 4.0%) 0 Reference Reference
≥ 1 24 (96.0%) 69 ( 100%) N/A N/A N/A
Ethnic Group 0.208
Chinese 22 (88.0%) 49 (71.0%) Reference Reference
Malay 2 ( 8.0%) 14 (20.3%) 0.318 (0.067-1.521) 0.216 0.272 (0.042-1.776) 0.174
Indian 1 ( 4.0%) 6 ( 8.7%) 0.371 (0.042-3.271) 0.667 0.182 (0.016-2.125) 0.174
Treatment Protocol 0.008
NUH 16 (64.0%) 18 (26.1%) Reference Reference
HK-SG 4 (16.0%) 24 (34.8%) 0.188 (0.053-0.657) 0.007 0.101 (0.021-0.475) 0.004
MA-SPORE 5 (20.0%) 27 (39.1%) 0.208 (0.065-0.670) 0.008 0.236 (0.057-0.970) 0.045
NQO1 C609T
CC 8 (32.0%) 24 (34.8%) Reference Reference
CT + TT 17 (68.0%) 45 (65.2%) 1.133 (0.427-3.006) 1.000 1.116 (0.336-3.712) 0.858
MTHFR C677T
CC 15 (60.0%) 42 (60.9%) Reference Reference
CT + TT 10 (40.0%) 27 (39.1%) 1.037 (0.407-2.641) 1.000 0.534 (0.165-1.728) 0.295
MTFHR A1298C
AA 14 (56.0%) 32 (46.4%) Reference Reference
AC + CC 11 (44.0%) 37 (53.6%) 0.680 (0.271-1.706) 0.487 0.486 (0.148-1.594) 0.234
CYP1A1 A4889G
AA 13 (52.0%) 37 (53.6%) Reference Reference






OR1 (95% CI) P1 OR2 (95% CI) P2
CYP 1A1 T6235C
TT 7 (28.0%) 24 (34.8%) Reference Reference
TC + CC 18 (72.0%) 45 (65.2%) 1.371 (0.503-3.742) 0.625 1.673 (0.345-8.103) 0.523
GSTP1 A105G
AA 17 (68.0%) 43 (62.3%) Reference Reference
AG + GG 8 (32.0%) 26 (37.7%) 0.778 (0.295-2.056) 0.808 0.646 (0.198-2.109) 0.469
MDR1 C3435T
CC 9 (36.0%) 26 (37.7%) Reference Reference
CT + TT 16 (64.0%) 43 (62.3%) 1.075 (0.415-2.782) 1.000 1.336 (0.400-4.462) 0.638
RFC G80A
GG 5 (20.0%) 18 (26.1%) Reference Reference
GA + AA 20 (80.0%) 51 (73.9%) 1.412 (0.462-4.317) 0.600 1.319 (0.265-6.573) 0.735
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[b]
Relapsed (n = 25) CR (n = 69) OR2 (95% CI) P2
NQO1 C609T
CC 8 (32.0%) 24 (34.8%) Reference
CT + TT 17 (68.0%) 45 (65.2%) 1.086 (0.395-2.980) 0.873
MTHFR C677T
CC 15 (60.0%) 42 (60.9%) Reference
CT + TT 10 (40.0%) 27 (39.1%) 0.953 (0.361-2.515) 0.922
MTFHR A1298C
AA 14 (56.0%) 32 (46.4%) Reference
AC + CC 11 (44.0%) 37 (53.6%) 0.631 (0.237-1.676) 0.355
CYP1A1 A4889G
AA 13 (52.0%) 37 (53.6%) Reference
AG +GG 12 (48.0%) 32 (46.4%) 0.676 (0.197-2.323) 0.534
CYP 1A1 T6235C
TT 7 (28.0%) 24 (34.8%) Reference
TC + CC 18 (72.0%) 45 (65.2%) 1.702 (0.446-6.493) 0.436
GSTP1 A105G
AA 17 (68.0%) 43 (62.3%) Reference
AG + GG 8 (32.0%) 26 (37.7%) 0.738 (0.272-2.007) 0.552
MDR1 C3435T
CC 9 (36.0%) 26 (37.7%) Reference
CT + TT 16 (64.0%) 43 (62.3%) 1.270 (0.470-3.432) 0.637
RFC G80A
GG 5 (20.0%) 18 (26.1%) Reference
GA + AA 20 (80.0%) 51 (73.9%) 1.665 (0.500-5.548) 0.407
Our multivariate analysis showed that among patients’ characteristics, neither the age
nor ethnic group is found to be associated with altered risk of ALL relapse while the
gender may have some influence (OR = 0.172, 95% CI 0.045-0.667, P-value = 0.011).
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The type of treatment protocol is also found to affect the risk of ALL relapse (P-value
= 0.008): compared with patients treated on NUH protocol, patients treated on HK-
SG or MA-SPORE protocol are at a lower risk of relapse (OR = 0.101, 95% CI 0.021-
0.475, P-value = 0.004; OR = 0.236, 95% CI 0.057-0.970, P-value = 0.045).
However, none of polymorphic loci included in the analysis is shown to correlate with
the risk of relapse.
As for this regression model constructed by patients’ characteristics and genotypes at
studied polymorphic loci, model coefficients are marginally significant (P-value =
0.052, 5% level of significance); in the Hosmer and Lemeshow test, the result is not
significant (P-value = 0.735, 5% level of significance); the predictive accuracy is
76.6% (72 out of 94).
In addition, we also tested 2 stepwise methods of data entry, i.e., “Forward: LR” and
“Backward: LR”. Both methods only retain the variable of “Protocol” in the
regression model finally (overall p-value = 0.005; for HK-SG vs. NUH, OR = 0.188,
95% CI 0.053-0.657, P-value = 0.009; for MA-SPORE vs. NUH, OR = 0.208, 95%
CI 0.065-0.670, P-value = 0.008).
As no genetic factors yielded significant results when non-genetic factors were
included in the regression model, we next constructed another model using genetic
factors alone as covariates. Again, none of genetic factors is found to be associated
with an altered risk of relapse using “Enter” method, and no covariate can be retained
in the final equation in any step-wise selection procedure.
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Due to the small sample size and component heterogeneity in this study, the
interpretation of above results should be done with caution.
3.2.8 Sensitivity comparison between APEX and AsPEX
To compare the sensitivity of APEX and AsPEX, both methods were carried out for
the same allele, TPMT A719. Table 3.9 shows the average signal intensity of A-
allele using different initial amounts of the DNA template. We applied both
parametric (independent t-test) and non-parametric (Mann-Whitney test) methods to
compare means. It appears clear that stronger signal intensity, as well as the
background noise, can be generated by AsPEX if the same amount of starting
materials is used for these two methods (Table 3.9 and Figure 3.8).
Table 3.9 Comparing sensitivity between APEX and AsPEX. The intensity values in
the table were the mean intensities of 4 replicates. P1 were calculated by independent
t-test for equality of means while P2 were calculated by Mann-Whitney test.
Initial DNA amount (ng)
0 25 50 100 200
APEX 2.2 3.1 8.2 19.9 26.9
AsPEX 4.2 19.2 70.6 93.2 104.0
P1 0.003 < 0.001 < 0.001 < 0.001 < 0.001
P2 0.021 0.021 0.021 0.021 0.021
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Figure 3.10 Comparing sensitivity between APEX and AsPEX. The error bars and
curves display the mean signal intensities from 4 replicates with 95% CI
corresponding to different amount of starting DNA. NTC, no-template-control.
3.2.9 Signal intensity of the AsPEX primer pair with balanced
concentration
To demonstrate potential extension bias for paired AsPEX primers, we tested 13
primer pairs individually using 13 samples heterozygous for the 13 polymorphisms
(except for CYP2D6 A2637del) studied in our work. The results are shown in Table
3.10. The AsPEX primer pairs for TPMT A539T, CYP1A1 A4889G and MDR1
C3435T generate very unbalanced signal intensities for two alleles (P < 0.05 in both t-
test and Mann-Whitney test) in respective heterozygote despite that the paired primers
are in the same concentration. In addition, for those pairs in which two primers
generate roughly equal signal intensity, the intensity is diverse among different targets.
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Table 3.10 Respective signal intensity ratio of paired AsPEX primers with balanced
concentrations. Final concentrations for all AsPEX primers were 2.5 nmol/L. The




A C G T
Signal ratio
(Allele 2 / Allele 1) #
TPMT G460A 103.8 95.6 1.09
TPMT A539T* 32.2 71.0 0.45
TPMT A719G 54.3 58.8 1.08
NQO1 C609T* 48.4 53.4 0.91
MTHFR C677T* 155.0 165.6 0.94
MTHFR A1298C 98.9 92.3 0.93
CYP1A1 C4887A 110.4 100.5 1.10
CYP1A1 A4889G* 61.1 136.7 0.45
CYP1A1 T6235C 64.3 52.5 1.22
CYP2D6 G1934A 42.4 38.5 1.10
GSTP1 A105G* 210.9 188.6 1.12
MDR1 C3435T* 55.8 67.2 0.83
RFC G80A* 77.0 162.2 2.11
* AsPEX primers were designed to anneal to the forward strand thus the nucleotides at primer terminals were
complementary to the nucleotides to be detected.
# Allele 1 is the wild-type allele.
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Chapter 4 Discussion
The earlier chapters have described the methodology and results of APEX and AsPEX
in detail. The first project focused on the development of a novel APEX-based DNA
chip used for screening polymorphisms causing β-thalassaemia and TPMT deficiency.
The second project, we designed a different chip-based genotyping system by
integrating the principle of AsPEX reaction and DNA microarray technology, and
applied this tool in a clinical study to investigate the impact of polymorphisms in
xenobiotics-metabolising genes on the risk of developing childhood ALL and the risk
of relapse among ALL patients.
In this chapter, we have organised the discussion of the experimental data and results
into two sections: the first section will focus on the technical issues regarding the
development of those two chip-based genotyping platforms; the second section will
decipher the clinical implications behind the statistical results and propose possible
biological mechanisms behind our findings.
4.1 Technical issues regarding the chip-based genotyping platforms
We developed 2 DNA chip-based genotyping platforms, based on similar principles:
arrayed primer extension (APEX) and allele-specific primer extension (AsPEX).
Both platforms have been validated using large sample sets and are reliable as
conventional but much more time-consuming genotyping techniques such as
Restriction Fragment Length Polymorphism (RFLP) and Allele-specific
Oligonucleotide (ASO) hybridisation.
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4.1.1 Comparison between APEX and AsPEX
APEX is derived from single nucleotide primer extension, or minisequencing, and
requires only one primer to query the polymorphic locus while AsPEX needs a primer
pair to detect a mutation. The primer used in the APEX or AsPEX reaction is
designed to anneal to the DNA sequence adjacent to the target position, and is
subjected to the extension of a single fluorescence-labelled nucleotide. Such a
modification will uncover the genotype in an imaging system. Beyond these
similarities, there are distinct differences between these two methods (Table 4.1).














APEX 1 Single strand No 2 No
4 samples by a set of
2 chips
AsPEX 2 Double strand Yes 1 Yes
2 samples by a single
chip
Firstly, minisequencing relies on the high accuracy of base-pairing principle and is
able to directly disclose the nucleotide at the queried locus. From this perspective,
minisequencing can be considered analogous to “Gold Standard” sequencing. In
contrast, AsPEX is an indirect method which depends on the polymerase’s
discrimination between matched and unmatched template-primer complex.
Occasionally, extension of unmatched primer may occur and leads to false
amplification. Therefore, AsPEX is theoretically less accurate than minisequencing.
To increase the robustness of AsPEX and decrease the possibility of non-specific
extension, we modified the common AsPEX methodology by replacing commonly
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used dNTP mix with ddNTP mix. The major advantage of using ddNTP is that
unmatched primer is difficult to form a stable 3’-end base-pairing duplex with a single
nucleotide addition, thus the polymerase is less likely to catalyse a ddNTP extension
compared to dNTP.
Secondly, APEX is a solid phase reaction, in which after hybridisation, the primer is
extended on the DNA chip. APEX primers are fixed on the chip thus cyclic
extensions of APEX primers not possible. In contrast AsPEX is performed in the
liquid phase, the primers are first extended and then hybridised on the chip. AsPEX
incorporates a cyclic reaction resulting in exponential formation of labelled
interrogating primers that is easily carried out using the common PCR thermocycler.
This is a significant advantage of AsPEX in that a high concentration of DNA
templates is not required while APEX reaction relies greatly on the template amount
to guarantee enough fluorescent intensity for a tested allele. Our sensitivity
comparison between APEX and AsPEX supports this advantage; using the same
amount of starting materials, AsPEX was able to generate much stronger signals than
APEX (Table 3.9 and Figure 3.8).
Single-stranded templates must be synthesized before APEX reaction while normal
double-stranded products of PCR can be used for AsPEX. Therefore, with the
restriction of having only one of the two template strands, APEX requires all
extension primers interrogating mutations in a single template to be in the same
direction whereas multiplex AsPEX does not have such a constraint. However,
despite the less flexible primer design, the space separation of APEX primers avoids
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the problem of primer-primer interactions which commonly occur in multiplex
AsPEX and making APEX easier to troubleshoot.
In conclusion, APEX and AsPEX each has its own advantages as well as drawbacks,
and may suit different genotyping needs: APEX is more appropriate to genotype a
single DNA sequence with multiple polymorphic alleles, like β-thalassaemia
mutations in the β-globin gene, while multiplex AsPEX is a better choice to genotype
multiple polymorphisms in multiple genes.
4.1.2 Comparisons between APEX/AsPEX and commercial chip-based
genotyping platforms
Chip-based genotyping techniques are also commercially available. Two famous
products are GeneChip® Human Mapping 500K Array Set (Affymetrix, Inc., USA)
and Sentrix HumanHap550 Genotyping BeadChip (Illumina, Inc, USA). Basically,
Affymetrix mapping array adopts the principle of ASO hybridisation while Illumina
beadchip is based on the strategy of AsPEX. A common feature of these two
techniques lies in the fact that multiple probe sets (or beads) are used to genotype one
SNP thus the genotyping accuracy can be achieved by such high redundancy. More
product details are available on the websites of two companies respectively
(Affymetrix: http://www.affymetrix.com/products/arrays/specific/500k.affx; Illumina:
http://www.illumina.com/products/arraysreagents/wgghumanhap550.ilmn).
Although in our study APEX and AsPEX are also chip-based genotyping approaches,
there are key differences in features and capabilities when compared to the two well-
established commercial products. Both mapping array and beadchip can cover over
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500,000 SNPs widespread in the whole human genome while APEX/AsPEX is
dedicated for a small number of specified targets. The huge differences in capacities
determine their different major applications: mapping array or beadchip is mainly
used for the whole genome association study rather than focused genotyping of
specific known polymorphisms of interest. In particular, these platforms are generally
used to determine the loss of heterozygosity (LOH), the copy number variations on
the genome scale, and the allele-specific copy number changes (Dutt and Beroukhim,
2007) while APEX/AsPEX is just designed to detect known polymorphisms in
specified genes. In addition, reaction kits, specialised analytical software as well as
comprehensive information database for data mining are all unique features for
commercial products. Customised techniques like APEX/AsPEX however do not
need such sophisticated analyses. Taken together, mapping arrays or beadchips are
undoubtedly more suited in genome-scale research compared to APEX/AsPEX which
is more hypothesis and candidate gene or pathway driven.
Customisation only for the target of interest is useful in routine clinical testing where
individual polymorphism detection rather than full-genome genotyping is required. It
also dispense with the need for difficult data mining or machine learning technology
to decipher the results. Finally, another critical issue for a technique is the assay cost,
especially for those used for clinical applications. Although mapping array or
Illumina beadchip is able to acquire much more information at the same time, they are
also rationally much more expensive than customised APEX/AsPEX methods.
Currently, the genotyping cost per sample using Affymetrix 500K Mapping Array Set
is nearly S$1,000; Illumina Sentrix HumanHap550 Genotyping BeadChip is slightly
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cheaper but still costs a few hundreds of dollars. In contrast, the assay cost in our
work using APEX or AsPEX was as low as S$7 per sample.
In conclusion, APEX/AsPEX and commercial chip-based genotyping platforms, e.g.,
Affymetrix mapping array or Illumina beadchip, are designed for different
applications. To genotype a few known SNPs in a small number of specified genes,
such as most routine screening work in clinical laboratories or investigations on allele
frequencies in a population, APEX/AsPEX is more suitable.
4.1.3 Comparisons between APEX/AsPEX and other genotyping
techniques
As DNA chip-based methods, the capacity for multiplexing is the most useful feature
of APEX and AsPEX methodologies. In our work, we successfully performed
simultaneous detections of 32 mutations in two genes using APEX and 14
polymorphisms in eight genes using AsPEX respectively.
With regards to multiplexing, APEX is more advantageous to the widely-used ASO
hybridisation for screening mutations in β-globin gene. The multi-ethnic origin of
populations in cosmopolitan cities, such as Singapore, calls for a method capable of
multiple mutation detection for the common genetic disorders like β-thalassaemia.
Although it is possible to devise reverse dot-blot (RDB) assays for the detection of
mutations found in a certain ethnic group, it is more difficult to organize ASO
hybridisation for more than 12 different mutations simultaneously. The main reason
is that when a large number of mutations are involved, it is often not possible to
design all oligonucleotide probes to allow hybridisation and stringent washing for all
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the normal and mutant probes at the same temperature. Currently such dot blots are
done in panels, where common limited panel of mutations are first screened followed
on by rarer mutations in a second or subsequent panels if a high degree of suspicion is
present.
The application of DNA chip technology enables the detection of multiple mutations
simultaneously. Although hybridisation to oligonucleotide arrays can be problematic,
in this study this was overcome by the generation of single-stranded templates in a
secondary PCR. This approach is cheaper than the treatment with exonucleases
(Shchepinov, et al., 1997a). Similarly, before our method of multiplex AsPEX,
polymorphisms in those eight genes in our study of childhood ALL were
conventionally screened by individual ASO hybridisation assays or PCR-RFLP tests
(Krajinovic, et al., 2002a, 2002c, 2004a; Laverdiere, et al., 2002). According to our
laboratory’s experience, to screen those 14 polymorphisms in the same set of samples,
multiplex AsPEX could achieve a throughput at least 10-fold higher than that for
conventional genotyping techniques without comprising accuracy.
Recently, two new high-throughput technologies that can be multiplexed have been
adopted for many genotyping purposes: Pyrosequencing and Fluorescent Polarization
Template-directed Dye Terminator Incorporation (FP-TDI) (Haglund, et al., 2004;
Okada, et al., 2005; Kwok, et al., 2002; Mo, et al., 2004). Compared to these two
methods, APEX and multiplex AsPEX can be time-saving and cost-effective.
Although multiplexed detection can be conducted in 96- or 384-well plate using
pyrosequencing or FP methodologies, individual reaction mix must be prepared for
each mutation to be detected. From this point of view, such a multiplexed detection is
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a combination of several singleplex reactions. If a large number of mutations are to
be screened simultaneously, it can be very laborious and expensive. On the contrary,
it is easier to prepare APEX and AsPEX reactions. A master mix of reagents is
applicable for all variants studied, thus saving time and costs.
4.1.4 Useful tips for the design of APEX/AsPEX DNA chip
Careful chip design is the key to ensure that the results are of good quality.
Pioneering studies have yielded much useful information in this area, such as
immobilization strategies (Lindroos, et al., 2001), effect of the DNA concentration
(Zammatteo, et al., 2000), hybridisation kinetics (Guo, et al., 1994; Shchepinov, et al.,
1997b), and background improvement (Diehl, et al., 2001). In our work, we
successfully simplified and optimised published protocols for the preparation of
spotted oligonucleotide arrays (Kurg, et al., 2000). Some useful experience is shared
below.
The size of DNA template used in APEX/AsPEX reaction
In APEX methodology, the product size of the first PCR may affect the yield of
isopropanol precipitation and the efficiency of the hybridisation. If the product size is
too small, the yield is usually low; on the contrary, if the size is too large, it increases
the possibility of non-specific hybridisation and the templates are more prone to form
secondary structures which may interfere with the hybridisation. Moreover, they may
cause steric hindrance on the solid support, thus compromising the efficiency of
hybridisation. Similarly, short PCR amplicons, which will be used as templates in
multiplex AsPEX, are easily lost during the purification. Long templates increase the
chances of non-specific template-template and template-primer interactions causing
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false fluorescent signals. To negate such effects, the PCR products were empirically
designed to be 200-300bp.
Oligonucleotide spacer
Additional oligonucleotide spacers are necessary for all APEX primers and
complementary tags of AsPEX primers. The reason is that the solid support may
cause steric hindrance and therefore interferes with hybridisation. Thus the primers or
tags need to be extended out of the slide surface to facilitate hybridisation. Guo, et al.,
(1994) has previously shown that hybridisation signal was virtually absent with poly
dT spacers less than 6 nucleotides. However, the signal increased strongly with
lengths up to 15 nucleotides. Further gains of signal strength may be attainable in this
fashion, albeit requiring more time and at the expense of oligonucleotide synthesis.
Shchepinov, et al., (1997b) also proved that the use of spacer molecules could reduce
steric interference of the support on the hybridisation behavior of immobilized
oligonucleotides. He found that the optimal spacer length should be at least 40 atoms
in length, giving up to 150-fold increase in hybridisation. In our work, we designed
the spacers of 15-25 nucleotides to balance the effect and the cost.
Besides the length, the sequence of oligonucleotide should be designed with caution
to avoid possible hairpin structure, which may also affect the hybridisation and cause
false signal.
Tm value of APEX/AsPEX primer
High Tm values are recommended for the designs of both APEX and AsPEX primers.
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In APEX methodology, the 3’ end of APEX primer is fixed at adjacent nucleotide of
polymorphic locus. The only variable parameter is the primer length, which, together
with GC content, determines the total Tm value of the primer. A comparatively high
Tm design is necessary since both the hybridisation and subsequent APEX reaction
are carried out at a slightly higher temperature, e.g. 60ºC in our protocol. A high Tm
design helps to stabilize template-primer binding, thus diminishing the loss of the
signal intensity. Furthermore, a high Tm design allows a high reaction temperature
which breaks down dimer structures between the primers or hairpin loops within the
primer itself, thus facilitating hybridisation and primer extension.
High Tm design benefits multiplex AsPEX in the same way because a high annealing
temperature can be applied, thus reducing the possibility of non-specific template-
primer and primer-primer interactions. This is crucial for correct primer extensions.
Fluorescent labels
According to our protocols, two different fluorescent labels (TAMRA and Cy5) and
two panels on the chip are required in APEX methodology to screen any DNA sample
for mutations while the method of multiplex AsPEX requires one dye (TAMRA) and
two panels to complete genotyping.
Theoretically, APEX utilise up to 4 different dyes to obtain the genotypes using only
a single chip, doubling the throughput of our method. However, according to our
experience, such a 4-dye application is not recommended. We tested FAM, Cy3,
Texas Red and Cy5 that are excited at commonly used wavelengths: 488nm, 543nm,
594nm and 633nm respectively. We found that when particular wavelength was used
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to scan the chip, the dyes of neighboring wavelength could be partially excited as well,
resulting in strong noise signals. Ideally only dyes of wavelengths that are distinctly
different to each other could be applied without causing non-specific excitation.
Although signal rectification could be addressed, the operation was very complicated
and not suitable for clinical use. Therefore we eventually adopted the current 2-dye
methodology to design APEX DNA chip.
4.1.5 Analyses of fluorescence intensity
In order to demonstrate that different genotypes could be clearly differentiated in
terms of signal strength, we analysed the ratios of fluorescent intensities in APEX and
AsPEX methods respectively.
In APEX methodology, we systematically determined 2 cut-off values, 5.0 and 10.0,
to interpret experimental data quantitatively according to the distribution of intensity
ratios (Section 3.1.4). In most cases, fluorescent signals could be easily identified on
the images and genotypes assigned accordingly. To avoid subjective errors, we
standardised the process by setting some criteria to filter out noise and determine the
real fluorescent signal. Using the cut-off value of 10.0, only about 0.5% of noise
would be wrongly predicted as real signals, indicating that any signal with the
intensity higher than 10.0 will probably be a real one. However, about 10% of real
signals were not strong enough to reach such a threshold. We therefore selected a
second cut-off value of 5.0, which would only miss about 3% real signals but
incorrectly identify 5% of noise as signals. The intensity between 5.0 and 10.0 may
be difficult to determine its class thus a repeated test as a confirming step is suggested.
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Similar analysis was also carried out for genotypes obtained by AsPEX methodology
and two values of 5.08 and 5.63 were selected.
In order to verify those cut-off values, one third of intensity data, which were not used
to generate ROC curves, were used as a validation set. The results showed that such
an independent data set yielded similar exceedingly accurate TPR and FPR compared
to those in the training set, indicating that such cut-off values can be also applied to
the future data.
4.1.6 Limitations of APEX and AsPEX
Unfortunately, no existing genotyping method is flawless, including APEX and
AsPEX. Although APEX and multiplex AsPEX methodologies can be applied to
detect nucleotide substitution, insertion, or small deletion involving only a few base
pairs, they are unable to detect large deletion. Both methods require the DNA
sequence spanning the entire mutant site to be amplified in the first round of PCR, and
this may not be possible for a large deletion. On the other hand, the determination of
a large deletion can be rapidly and simply performed by a common PCR reaction with
proper normal control making DNA chip seems unnecessary due to the higher assay
cost. The detection of large deletions was not included in our APEX methodology.
This accounts for our failure to detect the β-globin gene 619bp deletion (Section
3.1.3).
Moreover, it has been mentioned in the Section 4.1.1 (p129, the 2nd paragraph) that
cyclic amplification of fluorescent signals is difficult to perform in APEX format. If
the stock DNA is too diluted, it may not be able to generate sufficient single-stranded
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DNA (ssDNA) templates after two rounds of PCR reactions, which may cause weak
signal, and consequently the false negative result. This may explain the mistake of
Codon 8/9 wild-type assignment (Section 3.1.3). However, we acknowledge that it is
too difficult to identify the real cause as many factors can affect the signal intensity:
DNA quality, amplification bias, hybridisation efficiency, extension bias as well as
possible mis-operations during the assay preparation. We repeated the APEX assay
on a new sample aliquot and correctly obtained the genotype this time. It is noted that
even in the successful assay, unequal signal intensities of the two alleles was still
observed. Despite such unbalanced signals, our judgment on the genotype was not
affected as the decision was based on the absolute intensity of each allele rather than
the intensity ratio of the two. This is because the Cy3 and Cy5 were used in APEX
method and these two dyes have different fluorescent emission. To minimise the
uncertainty, it is crucial to obtain sufficient ssDNA products. Besides the method of
using PCR with single primer to generate ssDNA, an alternative way is to use a pair
of primers with unbalanced concentrations in the second round of PCR. However, we
compared these two strategies and found that they actually obtained similar yields if
the same amount of starting materials were used (Table 3.2).
Since multiplex AsPEX is a cyclic reaction conducted in liquid phase, the
concentration of DNA template in the mix is not a major obstacle. However, it is
more difficult to troubleshoot and optimise multiplex AsPEX. Numerous preliminary
tests must be conducted to determine suitable primer combinations as well as other
reaction conditions for the initial multiplex PCRs. Furthermore, the concentrations of
AsPEX primers must be adjusted individually and this adjustment requires expertise.
We observed that although a pair of AsPEX primers for a particular polymorphic
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locus differed only at 3’ end nucleotides, the polymerase might show clear preference
of nucleotide incorporation to this difference and consequently result in unbalanced
fluorescence intensity especially for heterozygous genotype (Table 3.10). This
preference may become a problem when the weaker signal appears to be false
negative. To resolve this problem, the concentration of the primer that gives weak
signal must be increased to compensate the fluorescent intensity. And it should be
borne in mind that increased primer concentration also implicates increased internal
competition between labelled primers and unlabelled primers during hybridisation.
Therefore, the adjustment for primer concentration requires a large number of tests to
obtain the optimal outcome. In our work, three pairs of AsPEX primers for TPMT
A539T, CYP1A1 A4889G and RFC G80A respectively were used in unbalanced
concentrations. Similarly, concentrations of the primer pairs among different loci
might also be different and required individual adjustment to produce optimal result.
In my work, they were either 2.5 nmol/L or 5.0 nmol/L in final reactant mix (Table
2.5b).
4.1.7 Future trends in genotyping technology
In Chapter 1, the principles and applications of several genotyping techniques
including APEX and AsPEX were described. Despite the numerous technical
advances in detection and multiplexing strategies, no technique clearly represents a
breakthrough.
In practice, the requirement of a PCR amplification step to achieve sensitive and
specific SNP genotyping is the principal factor that limits the throughput of assays
today (Syvanen, 2001). Multiplex PCR amplification of more than ten DNA
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fragments is difficult to carry out reproducibly owing to the generation of spurious
amplification products. A promising approach for avoiding non-specific primer
interactions in multiplex PCR is to carry out the amplifications with primers
immobilised at physically distinct locations in PCR colonies (Mitra, et al., 1999), gel
pads (Tillib, et al., 2001) or using microelectronic arrays (Westin, et al., 2000). SNP
genotyping by minisequencing or pyrosequencing will be compatible with these
formats. Moreover, PCR instruments that use microcapillaries instead of microtitre
plate formats have been devised and under validation, which promises increased PCR
throughputs and reduced reagent costs as they use extremely short amplification times
and small reaction volumes. Fully automated SNP analysis systems may be no longer
a dream by streamlining the PCR and the subsequent genotyping procedure in the
microfluidic devices that operate with submicrolitre reaction volumes. Such
microfluidic devices are currently under development (Mitchell, 2001).
Besides the improvements in the assay designs and instruments, new developments of
composite materials and fluorescence detection strategies may also revolutionise
genotyping assays by offering increased detection sensitivity and specificity. Hybrid
gold and silver nanoparticles have been used to replace conventional fluorophores as
labels on ASO probes (Taton, et al., 2000), enhancing the sensitivity of the assays by
two orders of magnitude. Another approach to highly multiplexed assays is to use
fibreoptic sensors to detect large numbers of coded microspheres in real time. For
SNP genotyping, coded microspheres that carry tag sequences would be captured in
miniaturised wells at the ends of fibreoptic detectors, and the signals that originate
from hybridisation, primer extension or oligonucleotide ligation reactions can be
monitored (Healey, et al., 1997). Finally, another very promising strategy for
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multiplexing bioassays involves using Quantum Dots (QDs) (Fortina, et al., 2005).
Multicolour optical coding is accomplished by embedding different sized QDs into
polymeric microbeads at precisely controlled ratios. Because of the unique spectral
properties of the QDs, this technology has the potential for several-thousand-fold
multiplexing.
In conclusion, an ideal technology for SNP analysis in the next generation should
integrate high throughput, robustness, accuracy, simplicity as well as low assay cost.
One thing is certain, once very-high-throughput SNP genotyping is available, this
technology will have a profound impact on our understanding of the relationship
between genetic variation and biological function.
4.2 Polymorphisms in xenobiotics-metabolising genes and their impact
on the risk of developing childhood ALL and risk of ALL relapse
Using multiplex AsPEX strategy, we screened 225 cases with childhood ALL and 334
healthy newborns for 14 polymorphisms in 8 genes: TPMT G460A, TPMT A539T,
TPMT A719G, NQO1 C609T, MTHFR C677T, MTHFR A1298C, CYP1A1 C4887A,
CYP1A1 A4889G, CYP1A1 T6235C, CYP2D6 G1934A, CYP2D6 A2637 deletion,
GSTP1 A105G, MDR1 C3435T and RFC G80A. We investigated respective
genotype/allele distributions in the population controls of 3 ethnic groups separately.
We also examined the impact of those polymorphisms on the risk of childhood ALL
and the risk of relapse among ALL patients.
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4.2.1 Significant differences in allele frequencies among Chinese, Malay
and Indian populations
We reported respective genotype distributions of those 14 polymorphisms in 129
Chinese, 104 Malay and 101 Indian individuals, and compared allele frequencies
among the three races using two-proportion z-test.
We observed that 7 out of 14 loci in our study show significant differences in allele
frequencies between Chinese and Indian, while only 3 loci display different
frequencies between Chinese and Malay. Besides, there are 4 loci that demonstrated
different allele frequencies between Malay and Indian. Such genotypic information
may help to elucidate observed inter-ethnic variability in the pharmacokinetics and
pharmacodynamics of certain drugs (Chowbay, et al., 2005). In addition, ethnic
differences in allele frequencies may also account for the fact that the a significant
risk-modifier of a certain disease (e.g., childhood ALL) in one population may not be
significant in another, as shown in our association study. Each population may have
its own susceptibility profile.
Besides the comparisons among those three ethnic groups, we also compared the
frequencies with corresponding findings in other previous reports. We observed that,
Chinese have a significantly higher NQO1*2 (T609) allele frequencies of 55.8%
(18.6% CC, 51.2% CT and 30.2% TT) compared with 25.0% (54.6% CC, 40.8% CT
and 4.6% TT) in Caucasian in Krajinovic’s report (Krajinovic, et al., 2002c). This is
consistent with another report in which NQO1*2 allele frequencies were found to be
49.0% in Chinese and 16.0% in Caucasians respectively (Gaedigk, et al., 1998).
Despite the difference of NQO1 C609T allele frequencies, Chinese and Caucasian
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have similar allele frequencies at other studied loci particularly at MTHFR C677T
locus at which genotype distributions are also remarkably similar: we detected 64.0%
C alleles and 36.0% T alleles (42.6% CC, 42.6% CT and 14.8% TT) while Krajinovic
reported 63.3% C alleles and 36.7% T alleles (42.0% CC, 42.7% CT and 15.3% TT)
in 300 healthy French-Canadians (Krajinovic, et al., 2004a).
Moreover, among all 14 polymorphisms studied, CYP2D6*3 (A2637 deletion) was
the only polymorphism absent. This result confirmed the early finding that
CYP2D6*3 is very rare in Asian populations (Ismail, et al., 2003; Kitada, 2003).
Our investigations on the allele frequencies of polymorphisms in xenobiotics-
metabolising genes provided additional evidence to support ethnic diversity of allele
frequencies. This study may be useful in the clinical use of relevant therapeutic drugs
which are subject to the metabolisms by the products of these genes.
4.2.2 The impact of MTHFR C677T, RFC G80A and NQO1 C609T
polymorphisms on the susceptibility to develop childhood ALL
We compared the genotype distributions of studied polymorphic loci (except for
CYP2D6*3) between the cases with childhood ALL and the population controls in
Chinese and Malays respectively. Statistical analyses for Indians were not performed
due to the underrepresented number of Indian patients (n = 18). We found that
compared with wild-types, MTHFR C677T variants are individually associated with a
reduced risk of developing childhood ALL in both Chinese and Malay populations
while NQO1 TT609 and RFC AA80 alter the risk in Chinese and Malays respectively.
Besides, we also examined the impact of certain combined genotypes, and identified a
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few genotype combinations that may alter the risk of developing childhood ALL in
Chinese or Malays. These findings are discussed below.
4.2.2.1 MTHFR C677T
In Chinese, 74 CC677 genotypes (55.2%) and 8 TT677 genotypes (6.0%) were
detected in patients while 55 CC677 genotypes (42.6%) and 19 TT677 genotypes
(14.8%) were detected in controls, representing a significant difference (OR = 0.313,
95% CI 0.128-0.767, crude p-value = 0.011). The odds ratio of 0.313 indicates a 3.2-
fold decreased risk of developing childhood ALL in carriers of TT677 genotype
compared to those of CC677 genotype. Even with the consideration of CT genotypes
together, the difference remains significant (OR = 0.603, 95% CI 0.370-0.981, P-
value = 0.049). This significance is probably due to the influence from homozygous
TT677 since CT677 heterozygosity does not demonstrate any significant impact on
the risk by itself. In Malays, no homozygous TT677 genotype was detected, whereas
CT677 genotypes is associated with a significant 2.4-fold decreased risk (OR = 0.411,
95% CI 0.186-0.908, P-value = 0.028). These findings support the speculation that
the enhanced availability of 5,10-methylene-THF in association with the reduced
MTHFR activity may play a protective role in the onset of childhood leukaemia.
The importance of MTHFR in cancer susceptibility arises from its involvement in 2
pathways of folate metabolism (Figure 1.9). One leads to numerous methylation
processes that are dependent on S-adenosylmethionine (SAM), while the other, via
thymidylate synthesis, contributes to DNA replication and cell division. Reduced
activity of MTHFR may decrease the methylation of homocysteine to methionine and
in turn lower the level of SAM, resulting in DNA hypomethylation (Kim, 1999). On
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the other hand, the reduced level of 5,10-methylene-THF, the MTHFR substrate
required for thymidylate synthesis, can lead to uracil misincorporation into DNA,
diminishing DNA repair and increasing the frequency of chromosomal breaks and
damage (Blount, et al., 1997; Choi, et al., 1998; Kim, 1999). Malignancies that are
derived from rapidly proliferating tissues, thus having great requirement for DNA
synthesis should be more susceptible to folate deficiency. Indeed, reduced MTHFR
activity caused by the polymorphisms has been associated with reduced risk of many
types of cancers including colorectal carcinoma, lymphoma and ALL in independent
studies (Chen, et al., 1996; Skibola, et al., 1999; Wiemels, et al., 2001; Matsuo, et al.,
2001). A logical explanation for this association is that increased availability of 5,10-
methylene-THF due to deficient MTHFR function enhances thymidine and purine
synthesis, which may slow the incorporation of uracil into DNA thus protecting
against carcinogenesis.
These findings support the previous results of Skibola, et al., (1999), who reported
reduced frequency of the TT677 in adult leukaemia, as well as results of Wiemels, et
al., (2001), who found the protective effect of MTHFR polymorphisms in infant
leukaemia with MLL rearrangements and hyperdiploid paediatric leukaemia.
However, we did not observe strong association between MTHFR A1298C and the
risk of developing childhood ALL. Compared with variant T677 which encodes
thermolabile enzyme with only 40% activity of that of the wild-type, homozygotes for
C1298 do not have the enzymatic properties distinguishable from the wild-type
MTHFR (Weisberg, et al., 2001). Decrease in enzyme activity is less than that of
T677 variant and does not appear to be sufficient to affect plasma homocysteine level
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(Freidamn, et al., 1999). Therefore, it is not surprising that no protective role of
C1298 has been identified in our work.
Interestingly, a trend towards increased risk was observed for AC1298 heterozygosity.
Only one previous study by Franco, et al., (2001) supports this finding. The
Ala222Val replacement caused by T677 variation is located in the region encoding
the N-terminal catalytic domain, whereas Glu429Ala substitution caused by C1298
variation resides within C-terminal SAM regulatory domain of the enzyme. It
remains unknown whether the different locations of these two polymorphisms in the
gene will pose different influences on role of MTHFR in the folate cycle. It is not
clear either whether these two polymorphisms are in linkage disequillibrium with
other polymorphisms and cause other specific gene-gene interactions. Furthermore
we cannot exempt the possibility that our study does not have enough statistical
power to detect a mild effect of C1298 on the leukemic risk. Further investigations
with larger sample sizes are required to confirm the role of C1298 in the susceptibility
to childhood ALL.
4.2.2.2 RFC G80A
As the observed genotype frequencies of RFC G80A polymorphism in the Chinese
controls were found to deviate significantly from their expected values according to
Hardy-Weinberg principle, risk analyses on this polymorphism were performed in
Malays only. In Malays, homozygous RFC AA80 is found to be strongly associated
with a reduced risk of developing childhood ALL (OR = 0.252, 95% CI 0.104-0.607,
P-value = 0.003, adjusted P-value = 0.009).
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Like MTHFR, RFC is another protein involved in folate metabolic pathway. The
natural folates are members of the class of vitamin B and are essential for cell
proliferation (Picciano, et al., 1990). Because mammalian cells cannot synthesise
these essential cofactors, folates must be actively transported into cell, whereupon
they participate in one-carbon transfer biosynthetic reactions leading to purines,
pyrimidines, serine, and methionine. The primary transport of folate from plasma into
cells is via RFC. As the predominant circulatory form of folate, 5-methyl-THF in
normal plasma may be the preferred substrate for cellular transport via RFC.
Therefore, the amino acid change from His to Arg (strong to weak basic amino acid)
in a first transmembrane domain (TMD1) caused by G80A substitution is expected to
alter RFC transport properties and influence endocellular level of 5-methyl-THF.
Surprisingly, this polymorphism in our study protects against development of
leukaemia in our Malay cohort something which seemed to contradict the common
understanding. A few studies previously showed that despite amino acid change, the
polymorphism did not cause notable functional differences in terms of folate affinities
and transport efficiencies compared with the wild-type (Chango, et al., 2000;
Whetstine, et al., 2001). On the contrary, the mutation could result in a major loss of
folate uptake while preserving sufficient reduced folate uptake to sustain cellular
growth (Kaufman, et al., 2004). It is not known whether this discrimination is the
cause. For example, this G-to-A substitution may enhance transporter’s affinity to
another substrate thus alter its content in the cell, which leads to the downstream
biological effect that decreases the risk of cancer. It is also noteworthy that A80 allele
is more prevalent than G80 in Chinese (58.8% versus 41.2%) and Malay (57.3%
versus 42.7%) according to our result, which is distinctly different from the
150
populations previously investigated. It is interesting to know whether the preference
for substrates and the capacity of folate uptake will be also different among different
ethnic groups.
To our best knowledge, this is the first study on RFC G80A in Asian populations.
Subsequent investigations using independent sample sets are necessary to validate the
impact of RFC G80A polymorphism on the risk of developing childhood ALL found
in our work.
4.2.2.3 NQO1 C609T
NQO1 is a flavin adenine dinucleotide-containing protein that catalyses the reduction
of quinines, quinoneimines, azo dyes and nitro groups. Being an obligate two-
electron reductase using either NADH or NADPH as an electron donor, NQO1
converts quinones to relatively stable hydroquinones that are subsequently subject to
conjugation and excretion. In this way, the production of semiquinone radicals is
bypassed, avoiding the generation of reactive oxygen species through interactions
between semiquinones and molecular oxygen (Gaedigk, et al., 1998). Furthermore,
NQO1 gene expression is inducible by oxidant stress, planar aromatic hydrocarbons,
phenolic antioxidants and a number of industrial acrylates and metals (Winner, et al.,
1997). Thus, NQO1 activity is generally viewed as protective against the potentially
toxic and carcinogenic effects of quinones and related structures.
There is considerable rationale to speculate that, since homozygous NQO1*2 (C-to-T
transition at position 609 in NQO1 gene) exhibits no enzymatic activity due to a
complete absence of NQO1 protein (Traver, et al., 1997), the homozygosity of this
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polymorphism is supposed to increase the risk of developing cancers. However, in
our study it is surprising to find that NQO1 TT609 genotype is strongly associated
with a decreased risk of developing childhood ALL in Chinese population (OR
=0.410, 95% CI 0.202-0.835, P-value = 0.042). Although the role of NQO1 in the
leukaemogenesis is still unclear, many studies have reported higher prevalence of the
NQO1*2 in leukaemia and other malignancies (Schulz, et al., 1997; Larson, et al.,
1999; Wiemels, et al., 1999; Clairmont, et al., 1999; Krajinovic, et al., 2002c).
Negative correlations were only found in lung cancer cases, in which over-
representation of wild-type NQO1 allele was identified (Wiencke, et al., 1997; Chen,
et al., 1999).
The frequency of NQO1*2 homozygosity varies across ethnic group from 4% in
Caucasians to 22% in Chinese populations (Kelsey, et al., 1997). Gaedigk, et al.,
(1998) reported that the NQO1*2 allele frequency is 16% in Caucasians and 49% in
Chinese. In Chinese healthy controls, the genotype frequency of TT609 is 30.2%
while the allele frequency of T609 is 55.8%, which is similar to those previous reports.
It is noteworthy that NQO1 is one of key enzymes handling exogenous xenobiotics
and such environmental exposures are lifestyle-specific. The long-term pressure of
natural selection leads to diverse allele and genotype frequencies between Caucasian
and Chinese. The gene expression and enzymatic function may also be moderately
altered as a type of adaptation to a particular environment. This can be a genetic basis
to account for our finding.
Although well known for its detoxification and antioxidation, NQO1 is also involved
in the bioactivation reactions. The chemical properties of the hydroquinone formed
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after NQO1 mediated reduction of a quinone determine whether NQO1 catalyses
activation or deactivation. Not all hydroquinones are chemically stable. In some
cases, the metabolism by NQO1 yields a more active product that can auto-oxidise to
produce reactive oxygen species or undergo rearrangement to generate alkylating
species (Figure 4.1). Redox-labile hydroquinones can react with molecular oxygen to
form semiquinones and generate reactive oxygen species, or semiquinones can be
generated via comproportionation reactions (Cadenas, 1995). In addition to
potentially causing oxidative stress through this mechanism, the reduction of the
quinone moiety can produce a compound that is capable of alkylating nucleophilic
sites including DNA (Ross, et al., 2000). This process, termed as “bio-reductive
alkylation”, may cause DNA damages such as inter-strand cross-links (Prakash, et al.,
1993) or DNA strand breaks (Beall, et al., 1996), thus is supposed to be carcinogenic.
Homozygous NQO1*2 genotype causes NQO1 deficiency and a protective effect is
consequently expected.
Figure 4.1 Activation and deactivation resulting from NQO1-mediated reduction of
quinones (adopted from Ross, et al., 2000).
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In conclusion, NQO1 is involved in a metabolism with two opposite effects, one of
which may become predominant in a particular environment. It is remains to be
proven whether the association between TT609 genotype and a decreased risk of
developing childhood ALL observed in Chinese in our study is due to this possibility.
Since our finding was the first report of such a protective role for NQO1
polymorphism in our geographic area, more studies are expected to confirm this
association.
4.2.2.4 The effects of combined genotypes
In addition to the univariant analysis on individual polymorphism, we also
investigated the effects of some combined genotypes that indicated gene-gene
interactions.
Combined genotypes at the loci of MTHFR C677T and A1298C were analysed in
both Chinese and Malays. We found that the composite genotypes of CT677/AA1298
and TT677/AA1298 are both associated with decreased risk of developing childhood
ALL in Chinese (for CT677/AA1298, OR = 0.413, 95% CI 0.192-0.887, P-value =
0.025; for TT677/AA1298, OR = 0.204, 95% CI 0.073-0.571, P-value = 0.003). This
appears consistent with previous analyses for individual locus: TT677 alone is
associated with a decreased risk; although not statistically significant, lower
frequency of CT677 in ALL cases than that in controls demonstrates a trend to protect
the development of ALL; and AA1298 may also play a protective role because C1298
has a higher frequency in the cases than in controls although the difference is not
significant, either. Therefore, it seems that AA1298 genotype is able to enhance the
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impact of T677 allele. The result from combined genotypes supports this speculation.
However, such effects were not observed in Malays.
The joint effects of the 2 polymorphisms, C677T and A1298C, in MTHFR have been
studied in Caucasians before (Skibola, et al., 1999; Krajinovic, et al., 2004). Like us,
Krajinovic, et al., (2004) also found TT677/AA1298 significant in his analyses while
Skibola reported significance only for the double heterozygosity CT677/AC1298.
Despite such discrepancies, variants in MTHFR gene are found to be associated with
a reduced risk of developing ALL in nearly all studies regardless of sampling
populations.
In addition, we also studied the combination of NQO1 C609T/MTHFR C677T in
Chinese, as they are found to be individually associated with a reduced risk in this
ethnic group. The results demonstrate the interaction between these two genes.
Compared to the results of univariate analyses in which only the homozygous variant
genotypes are shown to have impact on the risk, the impact of heterozygous variant in
one gene is enhanced by the variants in the other gene: CT609/TT677, TT609/CT677
and CT609/CT677 are all found to be statistically significant. In addition, the impact
associated with the two homozygous variants (i.e. NQO1 TT609 and MTHFR TT677)
is not affected when the other gene is wild-type (i.e. TT609/CC677 and
CC609/TT677). Interestingly, the compound homozygosity TT609/TT677, which is
supposed to be the most favorable genotype with lowest ALL risk compared to the
reference group CC609/CC677, does not show any association with the reduction in
the risk. However, considering that the observed frequencies of TT609/TT677 are
very low in controls (3, 2.3%) and ALL cases (3, 2.2%), lack of statistical power due
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to the small sample size analysed may account for our failure to identify significant
association.
In Malays, we analysed the combination of MTHFR C677T and RFC G80A because
they are the two polymorphisms found to be significantly associated with ALL risk.
Coincidently, both of them are involved in folate acid metabolic pathway. We
identified 2 composite genotypes that are statistically associated with a decreased risk
of developing ALL: CC677/AA80 (OR = 0.247, 95% CI 0.089-0.684, P-value =
0.008) and CT677/AA80 (OR = 0.136, 95% CI 0.008-0.545, P-value = 0.003).
Besides, CT677/GA80 may be another candidate as it shows a marginal significance
(OR = 0.297, 95% CI 0.089-0.997, P-value = 0.052). The associations implicated by
CC677/AA80 and CT677/AA80 are so strong that the significance can still remain
even after Bonferroni corrections for p-values. RFC AA80 alone was previously
shown to be a strong marker of the susceptibility to ALL (OR = 0.252, 95% CI 0.104-
0.607, P-value = 0.009). It appears that the influence of RFC overwhelms the effect
of MTHFR as the coexistence of wild-type CC609 is unable to alter the impact of
AA80. A possible explanation is that RFC has greater influence on the intracellular
folate content.
In the Section 1.2.3.8, Chapter 1, we described the issue of multiple comparisons in
statistics. In the analyses of combined genotypes, the more loci are included to form a
compound genotype, the more pair-wise comparisons are required, and consequently
the more likely the null hypothesis will be incorrectly rejected (known as false
positive). Methods such as the Bonferroni correction may be applied in this context
as a safeguard against the issue of multiple testing. However, it was also suggested
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that the correction for multiple comparisons was not required if a study, like ours, was
for exploratory purpose rather than making a decision (Krawcazk, et al., 2001). In
order to reduce the possibility of yielding false positives, the number of loci used to
construct a compound genotype was limited to two. In addition, the statistical results
were presented with and without the Bonferroni corrections while our data
interpretations were based on the values without corrections.
4.2.3 Factors that may alter the risk of relapse in children with ALL
In the Section 1.2.2, we described that except for two CYP genes, the other six genes
in our study are closely related to the metabolism of chemotherapeutic agents used for
ALL treatment. Previous investigation by Hongo has shown that drug resistance is
clearly related to induction failure and early relapse in childhood ALL (Hongo, et al.,
1997). Since enzyme dysfunction caused by the polymorphism in drug-metabolising
gene is one of frequently proposed mechanisms for the drug resistance, we speculated
that polymorphisms may be causative factors that can affect the treatment outcome.
In this study, the interest was the risk of relapse. Binary logistic regression analysis
was used to model the risk of relapse given genotypes of 8 polymorphic loci (the
other 6 loci were excluded in analyses due to underrepresented numbers of mutant
genotypes in our sample set) with or without patient’s characteristics including the
age, gender, ethnicity and treatment protocol.
In a complete model including patients’ characteristics and all studied loci, no
polymorphism is found to be associated with the risk of ALL relapse while the gender
(OR = 0.172, 95% CI 0.045-0.667, P-value = 0.011) and treatment protocol (overall
p-value = 0.008) show potential impact on the treatment outcome.
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Males are prone to suffer ALL relapse compared with females. This result is
consistent with the findings in most studies showing a better treatment outcome in
girls than in boys (Gaynon, et al., 2000; Harms, et al., 2000; Pui, et al., 2000). But
exceptions were also observed (Silverman, et al., 2000; Kamps, et al., 2000). The
mechanism still remains unknown. One explanation accounting for the worse
treatment outcome for boys is that higher rate of metabolising the drugs, particularly
6-MP and MTX, leads to inadequate systemic maintenance therapy. Boys tolerate
higher cumulative drug doses than girls, and it has been suggested that this tolerance
may be due to variable inheritance of sex-linked enzymes (Chessells, et al., 1995).
Concerning the treatment protocols, HK-SG protocol appeared to be better than NUH
protocol in terms of the number of relapsed cases. This is in line with the fact that
HK-SG protocol is more intensive than NUH protocol thus fewer relapsed cases are
expected, despite that enhanced intensity also leads to increased toxicity. MA-
SPORE is our current treatment protocol for childhood ALL patients and only
initiated about three years ago. Currently it is too early to make any conclusion
regarding this protocol. Comprehensive discussion on the treatment protocol is
beyond the scope of this thesis.
Considering the fact that genetic effects of each individual gene are probably modest
in a complex disease like ALL, it may not be a surprise that in a logistic regression
model no genetic factor could yield statistically significant contribution in the
presence of non-genetic factors that might have much stronger influence. We
therefore used genetic factors alone in a new model to see if any significant impact
could be revealed as well as to examine the relative strength of the contribution from
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each polymorphism. However, in such a model including only genotype frequencies
of different loci, no statistically significant result is yielded, either. All studied
polymorphisms appear to have little impact on the risk of ALL relapse. To discover
potential genetic markers associated with altered risk of ALL relapse, screening on a
whole-genome panel, rather than the candidate gene approach, may be required to
increase the overall genetic power of the study and accelerate the discovery process.
Our results pertaining to the risk of relapse should be interpreted with caution. Due to
very short follow up for most patients, only 25 relapsed cases and 69 patients in CR
for more than 2 years were eligible for the analysis. Considering the number of
predictors in the regression model, the issue of “overfitting” could not be excluded
due to the small sample size, despite the fact that the Hosmer and Lemeshow test
indicated a good match (P-value = 0.735) (Chan, 2004) between the predicted
probabilities for the covariates in the model and the observed probabilities. Sampling
bias as well as other potential factors may greatly influence the reliability of the
regression model thus limiting its accuracy of prediction for independent samples.
4.2.4 Limitations of the study
The value and reliability of our investigations on childhood ALL pharmacogenetics
may be limited by a few drawbacks.
Sample size has been frequently mentioned in earlier descriptions. Small sample size
may result in underpowered negative studies that often confuse rather than extend our
knowledge. In order to evaluate the sample size in our study, we carried out a post
hoc power analysis to calculate the desired sample size based on our actual sample
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size, observed allele frequencies and odds ratio. Although the results showed that for
most polymorphisms our sample size is indeed too small to achieve the statistical
significance given the observed odds ratios, those odds ratios are very close to 1
implying that such findings may not have much value in practice (Table 3.5c).
Despite that desired sample size can be roughly estimated through a priori power
analysis based on the results obtained at preliminary phase, if time and funding permit,
a study should recruit as many eligible samples as possible. Homogeneity is another
important feature to determine a “good” sample set. Homogeneity diminishes the
influence of potential confounding factors, for example, the ethnic diversity of allele
distribution at a particular polymorphic locus. Although our study enrolled 334
healthy controls and 225 ALL cases, the ethnicity had to be considered and separated
analysis should be performed, leading to a small sample size in each subgroup.
Another limitation is that gender effect was not considered in our investigation of
genotype frequencies for each polymorphic locus. Due to incomplete gender
information for the healthy controls, we were unable to investigate whether the allele
and genotype distributions of the polymorphisms were different in males and females.
This result might help to determine whether a gender-matched control group was
required to study the association between polymorphisms and the risk of developing
childhood ALL.
Moreover, since our study is the first report of the roles of some polymorphisms in an
epidemiological study of childhood ALL in Southeast Asian populations, we are not
sure whether our data are representative, especially for some “surprising” finding such
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as the protective role of NQO1 TT609. More studies are required to validate our
results.
4.2.5 Current obstacles in pharmacogenetics research of childhood ALL
and future directions
To date, TPMT polymorphism is the only example for which the role has been well
recognised in the pharmacogenetics of childhood ALL. No other polymorphism is
unequivocally associated with the susceptibility or the treatment outcomes. The
reasons for divergent results among studies include sample size, sample
characteristics, specimen quality, methodologies and treatment protocols.
Present day pharmacogenetics is limited to polymorphisms in enzymes with known
importance. Multiple elements including genetic variations are the determinants of
leukaemogenesis. Similarly, many proteins are involved in drug absorption,
intracellular transport, metabolism, modification, receptor interactions and excretion
(Weinshilboum, 2003). The ability to accurately quantify these variables is still
limited. As for the ALL therapy, any association of a polymorphism with outcome
may be protocol-specific; hence a significant association may not exist in another.
Despite these limitations, the pharmacogenetics of childhood ALL has a bright future.
As the rapid advance in high-throughput and low-cost genotyping technologies,
haplotype rather than genotype measures of genetic variation in relevant genes will be
applicable. A haplotype-based approach may provide a more complete and useful
assessment of genetic differences between individuals. Current research efforts focus
on developing haplotype maps across candidate genes. Additional work will be
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required to understand the sample size requirements of a haplotype-based approach
(Aplenc, et al., 2004). Future research should focus on the pathway analyses, rather
than single-gene studies, to access a stronger predictive power. Corresponding
improvement in the statistical methodologies is essential to suit the potentially high
number of possible haplotypes and discover gene-gene interactions.
We predict that studies on the genetic variations will eventually reveal the origin of
childhood ALL and revolutionise its therapy. Through multifaceted studies including
detailed pharmacogenetic profiling of each patient, we can better discern profiles that
predispose to development of ALL in children and unfavorable toxicity/response
profile. In so doing, we can more intelligently tailor the therapy to cure at “minimal
costs” and return the children with ALL to normalcy.
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